-DOCSTART-	O

Likewise	NN	O	O
,	NN	O	O
beta	NN	O	B-protein
2-M	NN	O	I-protein
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
markers	NN	O	O
of	NN	O	O
disease	NN	O	O
extension	NN	O	O
such	NN	O	O
as	NN	O	O
TNM	NN	O	O
,	NN	O	O
(	NN	O	O
UICC	NN	O	O
,	NN	O	O
classification	NN	O	O
of	NN	O	O
malignant	NN	O	B-cell_type
tumors	NN	O	I-cell_type
)	NN	O	O
staging	NN	O	O
and	NN	O	O
axillary	NN	O	O
lymph	NN	O	O
node	NN	O	O
involvement	NN	O	O
or	NN	O	O
with	NN	O	O
estrogen	NN	O	O
,	NN	O	O
progesterone	NN	O	O
,	NN	O	O
and	NN	O	O
glucocorticoid	NN	O	O
receptor	NN	O	O
levels	NN	O	O
.	NN	O	O

-DOCSTART-	O

Transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
interleukin-2	NN	O	I-DNA
(	NN	O	I-DNA
IL-2	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
,	NN	O	O
like	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
receptor	NN	O	I-DNA
alpha	NN	O	I-DNA
(	NN	O	I-DNA
IL-2R	NN	O	I-DNA
alpha	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
and	NN	O	O
the	NN	O	O
type	NN	O	O
1	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
(	NN	O	O
HIV-1	NN	O	O
)	NN	O	O
,	NN	O	O
is	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
modulated	NN	O	O
by	NN	O	O
a	NN	O	O
kappa	NN	O	B-protein
B-like	NN	O	I-protein
enhancer	NN	O	I-protein
element	NN	O	I-protein
.	NN	O	O

Novel	NN	O	O
region	NN	O	O
within	NN	O	O
the	NN	O	O
V	NN	O	B-DNA
kappa	NN	O	I-DNA
gene	NN	O	I-DNA
promoter	NN	O	I-DNA
is	NN	O	O
responsible	NN	O	O
for	NN	O	O
tissue	NN	O	O
and	NN	O	O
stage-specific	NN	O	O
expression	NN	O	O
of	NN	O	O
immunoglobulin	NN	O	B-DNA
genes	NN	O	I-DNA
in	NN	O	O
human	NN	O	B-cell_type
lymphoid	NN	O	I-cell_type
neoplasms	NN	O	I-cell_type
.	NN	O	O

Extracts	NN	O	O
of	NN	O	O
the	NN	O	O
B-cell	NN	O	B-cell_line
line	NN	O	I-cell_line
,	NN	O	O
BJA-B	NN	O	B-cell_line
,	NN	O	O
contain	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
NF-A2	NN	O	B-protein
and	NN	O	O
specifically	NN	O	O
transcribe	NN	O	O
Ig	NN	O	B-DNA
promoters	NN	O	I-DNA
.	NN	O	O

Calling	NN	O	O
T3	NN	O	O
100	NN	O	O
,	NN	O	O
the	NN	O	O
order	NN	O	O
of	NN	O	O
potencies	NN	O	O
observed	NN	O	O
was	NN	O	O
:	NN	O	O
Triac	NN	O	O
,	NN	O	O
500	NN	O	O
;	NN	O	O
3	NN	O	O
,	NN	O	O
5-diiodo-3'-isopropylthyronine	NN	O	O
,	NN	O	O
89	NN	O	O
;	NN	O	O
T4	NN	O	O
,	NN	O	O
32	NN	O	O
;	NN	O	O
3	NN	O	O
,	NN	O	O
5-dimethyl-3'isopropylthyronine	NN	O	O
2	NN	O	O
;	NN	O	O
3	NN	O	O
,	NN	O	O
5-T2	NN	O	O
,	NN	O	O
0.7	NN	O	O
,	NN	O	O
rT3	NN	O	O
,	NN	O	O
0.4	NN	O	O
;	NN	O	O
3'5'-T2	NN	O	O
,	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
.	NN	O	O

In	NN	O	O
B-lymphoblastoid	NN	O	B-cell_type
cell	NN	O	I-cell_type
lines	NN	O	I-cell_type
derived	NN	O	O
from	NN	O	O
two	NN	O	O
independent	NN	O	O
class	NN	O	O
II-deficient	NN	O	O
bare	NN	O	O
lymphocyte	NN	O	O
syndrome	NN	O	O
patients	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
a	NN	O	O
drastic	NN	O	O
decrease	NN	O	O
in	NN	O	O
transcription	NN	O	O
rates	NN	O	O
of	NN	O	O
the	NN	O	O
class	NN	O	B-DNA
II	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

Estradiol	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
the	NN	O	O
cytosol	NN	O	O
of	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
interferon-alpha	NN	O	B-protein
(	NN	O	O
IFN-alpha	NN	O	B-protein
)	NN	O	O
on	NN	O	O
estradiol	NN	O	B-protein
receptors	NN	O	I-protein
were	NN	O	O
studied	NN	O	O
in	NN	O	O
asymptomatic	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
carriers	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
and	NN	O	O
normal	NN	O	O
controls	NN	O	O
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

The	NN	O	O
ability	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
to	NN	O	O
inhibit	NN	O	O
interleukin	NN	O	B-protein
2	NN	O	I-protein
(	NN	O	O
IL	NN	O	B-protein
2	NN	O	I-protein
)	NN	O	O
-induced	NN	O	O
T	NN	O	B-cell_type
cell	NN	O	I-cell_type
proliferation	NN	O	O
in	NN	O	O
two	NN	O	O
cytotoxic	NN	O	B-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
(	NN	O	I-cell_line
CTL	NN	O	I-cell_line
)	NN	O	I-cell_line
clones	NN	O	I-cell_line
has	NN	O	O
been	NN	O	O
studied	NN	O	O
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
physiology	NN	O	O
of	NN	O	O
hematopoiesis	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
binding	NN	O	O
sites	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
modified	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
NK	NN	O	B-cell_type
effectors	NN	O	I-cell_type
with	NN	O	O
a	NN	O	O
monoclonal	NN	O	B-protein
anti-human	NN	O	I-protein
corticosteroid-binding	NN	O	I-protein
globulin	NN	O	I-protein
(	NN	O	I-protein
CBG	NN	O	I-protein
)	NN	O	I-protein
antibody	NN	O	I-protein
produced	NN	O	O
an	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
NK	NN	O	B-cell_type
activity	NN	O	O
and	NN	O	O
a	NN	O	O
partial	NN	O	O
suppression	NN	O	O
of	NN	O	O
cortisol-mediated	NN	O	O
effects	NN	O	O
.	NN	O	O

Data	NN	O	O
obtained	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
antiglucocorticoids	NN	O	O
and	NN	O	O
the	NN	O	O
anti-CBG	NN	O	B-protein
antibody	NN	O	I-protein
are	NN	O	O
compatible	NN	O	O
with	NN	O	O
a	NN	O	O
role	NN	O	O
both	NN	O	O
of	NN	O	O
high-affinity	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
and	NN	O	O
of	NN	O	O
CBG	NN	O	B-protein
in	NN	O	O
mediating	NN	O	O
cortisol	NN	O	O
action	NN	O	O
on	NN	O	O
the	NN	O	O
human	NN	O	B-cell_type
NK	NN	O	I-cell_type
cell	NN	O	I-cell_type
activity	NN	O	O
.	NN	O	O

Adhesion	NN	O	O
to	NN	O	O
extracellular	NN	O	O
matrices	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
modulate	NN	O	O
leukocyte	NN	O	O
activation	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
not	NN	O	O
fully	NN	O	O
understood	NN	O	O
.	NN	O	O

Some	NN	O	O
monocytes	NN	O	B-cell_type
and	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
stimulated	NN	O	O
with	NN	O	O
estradiol	NN	O	O
,	NN	O	O
PMA	NN	O	O
,	NN	O	O
and	NN	O	O
ionomycin	NN	O	O
.	NN	O	O

The	NN	O	O
presence	NN	O	O
of	NN	O	O
variants	NN	O	O
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
disease	NN	O	O
activity	NN	O	O
or	NN	O	O
medication	NN	O	O
.	NN	O	O

Apoptosis	NN	O	O
induced	NN	O	O
by	NN	O	O
DNA	NN	O	O
damage	NN	O	O
and	NN	O	O
other	NN	O	O
stresses	NN	O	O
can	NN	O	O
proceed	NN	O	O
via	NN	O	O
expression	NN	O	O
of	NN	O	O
Fas	NN	O	B-protein
ligand	NN	O	I-protein
(	NN	O	O
FasL	NN	O	B-protein
)	NN	O	O
and	NN	O	O
ligation	NN	O	O
of	NN	O	O
its	NN	O	O
receptor	NN	O	O
,	NN	O	O
Fas	NN	O	O
(	NN	O	O
CD95	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
stimuli	NN	O	O
also	NN	O	O
induced	NN	O	O
the	NN	O	O
stress-activated	NN	O	O
kinase	NN	O	O
pathway	NN	O	O
(	NN	O	O
SAPK/JNK	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
maximal	NN	O	O
induction	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
studied	NN	O	O
minimal	NN	O	O
residual	NN	O	O
disease	NN	O	O
(	NN	O	O
MRD	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
myeloid	NN	O	O
leukemia	NN	O	O
(	NN	O	O
AML	NN	O	O
)	NN	O	O
who	NN	O	O
have	NN	O	O
PML/RAR	NN	O	B-protein
alpha	NN	O	I-protein
or	NN	O	O
AML1/ETO	NN	O	B-protein
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
phenotypic	NN	O	O
analysis	NN	O	O
of	NN	O	O
lymphocyte	NN	O	B-cell_type
subsets	NN	O	I-cell_type
involved	NN	O	O
in	NN	O	O
antitumor	NN	O	O
immunity	NN	O	O
.	NN	O	O

Mycobacterium	NN	O	O
tuberculosis	NN	O	O
mannose-capped	NN	O	O
lipoarabinomannan	NN	O	O
can	NN	O	O
induce	NN	O	O
NF-kappaB	NN	O	B-protein
-dependent	NN	O	O
activation	NN	O	O
of	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
type	NN	O	I-DNA
1	NN	O	I-DNA
long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

M.	NN	O	O
tuberculosis	NN	O	O
ManLAM	NN	O	O
resulted	NN	O	O
in	NN	O	O
clear	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
luciferase	NN	O	B-DNA
gene	NN	O	I-DNA
placed	NN	O	O
under	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
wild-type	NN	O	B-DNA
,	NN	O	I-DNA
but	NN	O	I-DNA
not	NN	O	I-DNA
the	NN	O	I-DNA
kappaB-mutated	NN	O	I-DNA
,	NN	O	I-DNA
HIV-1	NN	O	I-DNA
LTR	NN	O	I-DNA
region	NN	O	I-DNA
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
the	NN	O	O
ManLAM-mediated	NN	O	O
activation	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
LTR	NN	O	O
transcription	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
independent	NN	O	O
of	NN	O	O
the	NN	O	O
autocrine	NN	O	O
or	NN	O	O
paracrine	NN	O	O
action	NN	O	O
of	NN	O	O
endogenous	NN	O	B-protein
TNF-alpha	NN	O	I-protein
.	NN	O	O

In	NN	O	O
flies	NN	O	O
,	NN	O	O
this	NN	O	O
pathway	NN	O	O
controls	NN	O	O
segment	NN	O	O
polarity	NN	O	O
;	NN	O	O
in	NN	O	O
Xenopus	NN	O	O
it	NN	O	O
controls	NN	O	O
the	NN	O	O
definition	NN	O	O
of	NN	O	O
the	NN	O	O
body	NN	O	O
axis	NN	O	O
.	NN	O	O

These	NN	O	O
insights	NN	O	O
in	NN	O	O
the	NN	O	O
molecular	NN	O	O
events	NN	O	O
that	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
TCF/LEF	NN	O	B-protein
function	NN	O	O
in	NN	O	O
these	NN	O	O
organisms	NN	O	O
may	NN	O	O
eventually	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
understanding	NN	O	O
of	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
these	NN	O	O
HMG	NN	O	B-protein
box	NN	O	I-protein
proteins	NN	O	I-protein
in	NN	O	O
lymphoid	NN	O	O
development	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
that	NN	O	O
the	NN	O	O
PCD/DCoH	NN	O	B-RNA
mRNA	NN	O	I-RNA
is	NN	O	O
present	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
white	NN	O	I-cell_type
blood	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
hair	NN	O	O
follicles	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
in	NN	O	O
class	NN	O	B-cell_type
II+	NN	O	I-cell_type
mature	NN	O	I-cell_type
B-cells	NN	O	I-cell_type
NF-Y	NN	O	B-protein
is	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
protein	NN	O	O
cofactor	NN	O	O
,	NN	O	O
PC4	NN	O	B-protein
,	NN	O	O
which	NN	O	O
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
NF-Y-mediated	NN	O	O
transcriptional	NN	O	O
control	NN	O	O
of	NN	O	O
class	NN	O	B-DNA
II	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

Stable	NN	O	O
adhesion	NN	O	O
of	NN	O	O
leukocytes	NN	O	B-cell_type
to	NN	O	O
glucose-treated	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
to	NN	O	O
IL-1beta-stimulated	NN	O	B-cell_type
endothelial	NN	O	I-cell_type
cells	NN	O	I-cell_type
was	NN	O	O
preceded	NN	O	O
by	NN	O	O
short	NN	O	O
interaction	NN	O	O
of	NN	O	O
leukocytes	NN	O	B-cell_type
with	NN	O	O
the	NN	O	O
endothelial	NN	O	O
surface	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
review	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
Ikaros	NN	O	B-protein
,	NN	O	O
the	NN	O	O
founding	NN	O	O
member	NN	O	O
of	NN	O	O
a	NN	O	O
unique	NN	O	O
family	NN	O	O
of	NN	O	O
zinc	NN	O	B-protein
finger	NN	O	I-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
in	NN	O	O
this	NN	O	O
developmental	NN	O	O
process	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
ectopic	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
E2A	NN	O	B-protein
protein	NN	O	O
E12	NN	O	B-protein
in	NN	O	O
this	NN	O	O
macrophage	NN	O	B-cell_line
line	NN	O	I-cell_line
results	NN	O	O
in	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
many	NN	O	B-DNA
B	NN	O	I-DNA
lineage	NN	O	I-DNA
genes	NN	O	I-DNA
,	NN	O	O
including	NN	O	O
EBF	NN	O	B-protein
,	NN	O	O
IL7Ralpha	NN	O	B-protein
,	NN	O	O
lambda5	NN	O	B-protein
,	NN	O	O
and	NN	O	O
Rag-1	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
induce	NN	O	O
kappa	NN	O	B-protein
light	NN	O	I-protein
chain	NN	O	I-protein
in	NN	O	O
response	NN	O	O
to	NN	O	O
mitogen	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
RXRalpha	NN	O	B-RNA
mRNA	NN	O	I-RNA
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
regulated	NN	O	O
at	NN	O	O
the	NN	O	O
post-transcriptional	NN	O	O
level	NN	O	O
and	NN	O	O
involved	NN	O	O
new	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
.	NN	O	O

-DOCSTART-	O

Among	NN	O	O
patients	NN	O	O
with	NN	O	O
congenital	NN	O	O
and	NN	O	O
acquired	NN	O	O
immunodeficiencies	NN	O	O
,	NN	O	O
non-Hodgkin	NN	O	O
's	NN	O	O
lymphoma	NN	O	O
(	NN	O	O
NHLs	NN	O	O
)	NN	O	O
are	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
tumors	NN	O	O
of	NN	O	O
the	NN	O	O
immune	NN	O	O
system	NN	O	O
.	NN	O	O

Specific	NN	O	O
forms	NN	O	O
of	NN	O	O
HIV-associated	NN	O	O
NHL	NN	O	O
are	NN	O	O
linked	NN	O	O
to	NN	O	O
expression	NN	O	O
of	NN	O	O
Epstein-Barr	NN	O	B-protein
virus	NN	O	I-protein
(	NN	O	I-protein
EBV	NN	O	I-protein
)	NN	O	I-protein
-latent	NN	O	I-protein
proteins	NN	O	I-protein
;	NN	O	O
the	NN	O	O
newly	NN	O	O
described	NN	O	O
DNA	NN	O	O
virus	NN	O	O
,	NN	O	O
Karposi	NN	O	O
's	NN	O	O
sarcoma-associated	NN	O	O
herpesvirus/human	NN	O	O
herpesvirus-8	NN	O	O
(	NN	O	O
KSHV/HHV-8	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
perhaps	NN	O	O
HIV	NN	O	O
.	NN	O	O

Stromelysin-1	NN	O	B-protein
(	NN	O	O
ST1	NN	O	B-protein
)	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
about	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
epithelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
the	NN	O	O
control	NN	O	O
groups	NN	O	O
(	NN	O	O
cases	NN	O	O
of	NN	O	O
fibrocystic	NN	O	O
and	NN	O	O
benign	NN	O	O
proliferative	NN	O	O
breast	NN	O	O
disease	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
expression	NN	O	O
(	NN	O	O
>	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
expression	NN	O	O
)	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
89.7	NN	O	O
%	NN	O	O
of	NN	O	O
tumours	NN	O	O
.	NN	O	O

Local	NN	O	O
hypoxemia	NN	O	O
and	NN	O	O
stasis	NN	O	O
trigger	NN	O	O
thrombosis	NN	O	O
.	NN	O	O

Steady-state	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
of	NN	O	O
IL-2	NN	O	B-protein
,	NN	O	O
IL-10	NN	O	B-protein
and	NN	O	O
IFN-gamma	NN	O	B-protein
peaked	NN	O	O
at	NN	O	O
3	NN	O	O
hr	NN	O	O
after	NN	O	O
anti-CD3	NN	O	O
stimulation	NN	O	O
and	NN	O	O
declined	NN	O	O
rapidly	NN	O	O
thereafter	NN	O	O
.	NN	O	O

Downstream	NN	O	O
effectors	NN	O	O
of	NN	O	O
the	NN	O	O
MAPK	NN	O	O
signal	NN	O	O
transduction	NN	O	O
cascades	NN	O	O
include	NN	O	O
MAPKAP	NN	O	B-protein
kinases	NN	O	I-protein
,	NN	O	O
such	NN	O	O
as	NN	O	O
RSK1	NN	O	B-protein
and	NN	O	O
RSK2	NN	O	B-protein
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

By	NN	O	O
representative	NN	O	O
difference	NN	O	O
analysis	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
CRABP	NN	O	B-protein
II	NN	O	I-protein
is	NN	O	O
also	NN	O	O
strongly	NN	O	O
expressed	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocyte-derived	NN	O	I-cell_type
macrophages	NN	O	I-cell_type
(	NN	O	O
MAC	NN	O	B-cell_type
)	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
freshly	NN	O	B-cell_type
isolated	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
(	NN	O	O
MO	NN	O	B-cell_type
)	NN	O	O
.	NN	O	O

From	NN	O	O
these	NN	O	O
results	NN	O	O
we	NN	O	O
conclude	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
that	NN	O	O
the	NN	O	O
availability	NN	O	O
and	NN	O	O
the	NN	O	O
metabolism	NN	O	O
of	NN	O	O
retinoids	NN	O	O
may	NN	O	O
be	NN	O	O
different	NN	O	O
in	NN	O	O
MAC	NN	O	B-cell_type
compared	NN	O	O
to	NN	O	O
MO	NN	O	B-cell_type
and	NN	O	O
dendritic	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
that	NN	O	O
this	NN	O	O
may	NN	O	O
influence	NN	O	O
differentiation	NN	O	O
and	NN	O	O
activation	NN	O	O
of	NN	O	O
those	NN	O	O
cells	NN	O	O
.	NN	O	O

All	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
(	NN	O	O
100	NN	O	O
%	NN	O	O
)	NN	O	O
B-cell	NN	O	O
chronic	NN	O	O
lymphocytic	NN	O	O
leukemias	NN	O	O
(	NN	O	O
B-CLLs	NN	O	O
)	NN	O	O
,	NN	O	O
21	NN	O	O
of	NN	O	O
(	NN	O	O
100	NN	O	O
%	NN	O	O
)	NN	O	O
mantle	NN	O	B-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
MCLs	NN	O	B-cell_type
)	NN	O	O
,	NN	O	O
and	NN	O	O
20	NN	O	O
of	NN	O	O
21	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
)	NN	O	O
follicular	NN	O	O
lymphomas	NN	O	O
(	NN	O	O
FLs	NN	O	O
)	NN	O	O
were	NN	O	O
positive	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
23	NN	O	O
T-	NN	O	O
and	NN	O	O
null-cell	NN	O	O
lymphomas	NN	O	O
reacted	NN	O	O
with	NN	O	O
the	NN	O	O
BSAP	NN	O	B-protein
antisera	NN	O	O
,	NN	O	O
whereas	NN	O	O
in	NN	O	O
Hodgkin	NN	O	O
's	NN	O	O
disease	NN	O	O
,	NN	O	O
2	NN	O	O
of	NN	O	O
4	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
nodular	NN	O	O
lymphocytic	NN	O	O
predominance	NN	O	O
and	NN	O	O
5	NN	O	O
of	NN	O	O
14	NN	O	O
(	NN	O	O
36	NN	O	O
%	NN	O	O
)	NN	O	O
classical	NN	O	O
cases	NN	O	O
showed	NN	O	O
weak	NN	O	O
nuclear	NN	O	O
or	NN	O	O
nucleolar	NN	O	O
BSAP	NN	O	B-protein
reactions	NN	O	O
in	NN	O	O
a	NN	O	O
fraction	NN	O	O
of	NN	O	O
the	NN	O	O
tumor	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

Bcl-3	NN	O	B-protein
expression	NN	O	O
and	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
are	NN	O	O
induced	NN	O	O
by	NN	O	O
granulocyte-macrophage	NN	O	B-protein
colony-stimulating	NN	O	I-protein
factor	NN	O	I-protein
and	NN	O	O
erythropoietin	NN	O	B-protein
in	NN	O	O
proliferating	NN	O	B-cell_type
human	NN	O	I-cell_type
erythroid	NN	O	I-cell_type
precursors	NN	O	I-cell_type
.	NN	O	O

Overexpression	NN	O	O
of	NN	O	O
Bcl-3	NN	O	B-protein
in	NN	O	O
TF-1	NN	O	B-cell_line
cells	NN	O	I-cell_line
by	NN	O	O
transient	NN	O	O
transfection	NN	O	O
along	NN	O	O
with	NN	O	O
the	NN	O	O
NF-kappaB	NN	O	B-protein
factors	NN	O	I-protein
p50	NN	O	I-protein
or	NN	O	I-protein
p52	NN	O	I-protein
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
induction	NN	O	O
of	NN	O	O
an	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus-type	NN	O	I-DNA
1	NN	O	I-DNA
(	NN	O	I-DNA
HIV-1	NN	O	I-DNA
)	NN	O	I-DNA
kappaB-TATA-luceriferase	NN	O	I-DNA
reporter	NN	O	I-DNA
plasmid	NN	O	I-DNA
,	NN	O	O
demonstrating	NN	O	O
that	NN	O	O
Bcl-3	NN	O	B-protein
has	NN	O	O
a	NN	O	O
positive	NN	O	O
role	NN	O	O
in	NN	O	O
transactivation	NN	O	O
of	NN	O	O
kappaB-containing	NN	O	B-DNA
genes	NN	O	I-DNA
in	NN	O	O
erythroid	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

A	NN	O	O
region	NN	O	O
of	NN	O	O
basic	NN	O	O
amino	NN	O	O
acids	NN	O	O
spanning	NN	O	O
residues	NN	O	B-protein
639-656	NN	O	I-protein
in	NN	O	O
the	NN	O	O
human	NN	O	B-protein
5-lipoxygenase	NN	O	I-protein
sequence	NN	O	I-protein
resembles	NN	O	O
a	NN	O	O
consensus	NN	O	B-protein
bipartite	NN	O	I-protein
nuclear	NN	O	I-protein
localizing	NN	O	I-protein
sequence	NN	O	I-protein
.	NN	O	O

In	NN	O	O
cells	NN	O	O
treated	NN	O	O
with	NN	O	O
agents	NN	O	O
that	NN	O	O
block	NN	O	O
5-lipoxygenase	NN	O	B-protein
translocation	NN	O	O
to	NN	O	O
the	NN	O	O
nucleus	NN	O	O
,	NN	O	O
5-lipoxygenase	NN	O	B-protein
protein	NN	O	O
appearing	NN	O	O
in	NN	O	O
the	NN	O	O
NF-kappaB	NN	O	B-protein
immunoprecipitate	NN	O	O
was	NN	O	O
diminished	NN	O	O
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
results	NN	O	O
in	NN	O	O
a	NN	O	O
rapid	NN	O	O
increase	NN	O	O
in	NN	O	O
intracellular	NN	O	O
calcium	NN	O	O
concentration	NN	O	O
(	NN	O	O
[	NN	O	O
Ca2+	NN	O	O
]	NN	O	O
i	NN	O	O
)	NN	O	O
that	NN	O	O
parallels	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
Ca2+-calmodulin-dependent	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
IV	NN	O	I-protein
(	NN	O	O
CaMKIV	NN	O	B-protein
)	NN	O	O
,	NN	O	O
a	NN	O	O
nuclear	NN	O	B-protein
enzyme	NN	O	I-protein
that	NN	O	O
can	NN	O	O
phosphorylate	NN	O	O
and	NN	O	O
activate	NN	O	O
the	NN	O	O
cyclic	NN	O	B-protein
adenosine	NN	O	I-protein
monophosphate	NN	O	I-protein
(	NN	O	I-protein
cAMP	NN	O	I-protein
)	NN	O	I-protein
response	NN	O	I-protein
element-binding	NN	O	I-protein
protein	NN	O	I-protein
(	NN	O	O
CREB	NN	O	B-protein
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Activation	NN	O	O
of	NN	O	O
NF	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
was	NN	O	O
determined	NN	O	O
by	NN	O	O
western	NN	O	O
blot	NN	O	O
assessment	NN	O	O
and	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assay	NN	O	O
in	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
of	NN	O	O
colonic	NN	O	O
biopsy	NN	O	O
samples	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
lamina	NN	O	B-cell_type
propria	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
clarify	NN	O	O
the	NN	O	O
histogenesis	NN	O	O
and	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
these	NN	O	O
lymphomas	NN	O	O
,	NN	O	O
49	NN	O	O
PCNSL	NN	O	O
(	NN	O	O
26	NN	O	O
acquired	NN	O	O
immunodeficiency	NN	O	O
syndrome	NN	O	O
[	NN	O	O
AIDS	NN	O	O
]	NN	O	O
-related	NN	O	O
and	NN	O	O
23	NN	O	O
AIDS-unrelated	NN	O	O
)	NN	O	O
were	NN	O	O
analyzed	NN	O	O
for	NN	O	O
multiple	NN	O	O
biologic	NN	O	O
markers	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
known	NN	O	O
to	NN	O	O
bear	NN	O	O
histogenetic	NN	O	O
and	NN	O	O
pathogenetic	NN	O	O
significance	NN	O	O
for	NN	O	O
mature	NN	O	O
B-cell	NN	O	O
neoplasms	NN	O	O
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
a	NN	O	O
meaningful	NN	O	O
relationship	NN	O	O
between	NN	O	O
receptor	NN	O	O
expression	NN	O	O
and	NN	O	O
known	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
glucocorticoids	NN	O	O
.	NN	O	O

Further	NN	O	O
,	NN	O	O
we	NN	O	O
find	NN	O	O
that	NN	O	O
HEB	NN	O	B-DNA
driven	NN	O	O
by	NN	O	O
the	NN	O	O
endogenous	NN	O	B-DNA
E2A	NN	O	I-DNA
promoter	NN	O	I-DNA
can	NN	O	O
functionally	NN	O	O
replace	NN	O	O
E2A	NN	O	B-DNA
in	NN	O	O
supporting	NN	O	O
B-cell	NN	O	O
commitment	NN	O	O
and	NN	O	O
differentiation	NN	O	O
toward	NN	O	O
completion	NN	O	O
.	NN	O	O

-DOCSTART-	O

CD80	NN	O	B-protein
induced	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
-enhancer	NN	O	O
activity	NN	O	O
compared	NN	O	O
to	NN	O	O
CD86	NN	O	B-protein
.	NN	O	O

DR3	NN	O	B-protein
is	NN	O	O
capable	NN	O	O
of	NN	O	O
inducing	NN	O	O
both	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
when	NN	O	O
overexpressed	NN	O	O
in	NN	O	O
mammalian	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
although	NN	O	O
its	NN	O	O
ligand	NN	O	O
has	NN	O	O
not	NN	O	O
yet	NN	O	O
been	NN	O	O
identified	NN	O	O
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
lysis	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
temperature	NN	O	O
dependent	NN	O	O
and	NN	O	O
was	NN	O	O
detected	NN	O	O
only	NN	O	O
after	NN	O	O
6	NN	O	O
to	NN	O	O
8	NN	O	O
hr	NN	O	O
incubation	NN	O	O
with	NN	O	O
cortisol	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
the	NN	O	O
trypan	NN	O	O
blue	NN	O	O
exclusion	NN	O	O
test	NN	O	O
.	NN	O	O

An	NN	O	O
excess	NN	O	O
of	NN	O	O
an	NN	O	O
antagonist	NN	O	O
such	NN	O	O
as	NN	O	O
cortexolone	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
inhibit	NN	O	O
the	NN	O	O
cortisol-induced	NN	O	O
cytolysis	NN	O	O
of	NN	O	O
the	NN	O	O
CLL	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
has	NN	O	O
been	NN	O	O
a	NN	O	O
positive	NN	O	O
correlation	NN	O	O
,	NN	O	O
in	NN	O	O
our	NN	O	O
hands	NN	O	O
,	NN	O	O
with	NN	O	O
receptor	NN	O	O
level	NN	O	O
and	NN	O	O
prognosis	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
investigated	NN	O	O
this	NN	O	O
syndrome	NN	O	O
for	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
abnormal	NN	O	B-protein
Type	NN	O	I-protein
I	NN	O	I-protein
or	NN	O	O
``	NN	O	B-protein
mineralocorticoid-like	NN	O	I-protein
''	NN	O	I-protein
receptors	NN	O	I-protein
,	NN	O	O
which	NN	O	O
have	NN	O	O
intrinsic	NN	O	O
steroid	NN	O	O
specificity	NN	O	O
indistinguishable	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
renal	NN	O	B-protein
mineralocorticoid	NN	O	I-protein
receptors	NN	O	I-protein
and	NN	O	O
are	NN	O	O
found	NN	O	O
in	NN	O	O
many	NN	O	O
tissues	NN	O	O
and	NN	O	O
cells	NN	O	B-cell_type
,	NN	O	O
including	NN	O	O
mononuclear	NN	O	B-cell_type
leukocytes	NN	O	I-cell_type
.	NN	O	O

Levels	NN	O	O
in	NN	O	O
the	NN	O	O
parents	NN	O	O
of	NN	O	O
the	NN	O	O
Munich	NN	O	O
patients	NN	O	O
(	NN	O	O
first	NN	O	O
cousins	NN	O	O
)	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
both	NN	O	O
HMy2	NN	O	B-cell_line
and	NN	O	I-cell_line
GM4672A	NN	O	I-cell_line
cells	NN	O	I-cell_line
with	NN	O	O
Dex	NN	O	O
for	NN	O	O
1-4	NN	O	O
days	NN	O	O
inhibits	NN	O	O
extracellular	NN	O	O
PA	NN	O	B-protein
activity	NN	O	O
in	NN	O	O
a	NN	O	O
concentration-dependent	NN	O	O
manner	NN	O	O
,	NN	O	O
being	NN	O	O
half-maximal	NN	O	O
at	NN	O	O
approximately	NN	O	O
1	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-9	NN	O	O
)	NN	O	O
M	NN	O	O
.	NN	O	O

The	NN	O	O
capacity	NN	O	O
and	NN	O	O
the	NN	O	O
affinity	NN	O	O
of	NN	O	O
dexamethasone	NN	O	O
for	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
ranged	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
values	NN	O	O
.	NN	O	O

Content	NN	O	O
of	NN	O	O
receptors	NN	O	O
in	NN	O	O
cytosol	NN	O	O
of	NN	O	O
blood	NN	O	O
leukocytes	NN	O	O
was	NN	O	O
studied	NN	O	O
using	NN	O	O
3H-triamcinolone	NN	O	O
acetonide	NN	O	O
.	NN	O	O

In	NN	O	O
acute	NN	O	O
pancreatitis	NN	O	O
content	NN	O	O
of	NN	O	O
the	NN	O	O
leukocyte	NN	O	B-protein
receptors	NN	O	I-protein
was	NN	O	O
not	NN	O	O
altered	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

Concentration	NN	O	O
of	NN	O	O
endogenous	NN	O	O
cortisol	NN	O	O
was	NN	O	O
increased	NN	O	O
in	NN	O	O
blood	NN	O	O
of	NN	O	O
all	NN	O	O
the	NN	O	O
patients	NN	O	O
,	NN	O	O
except	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
of	NN	O	O
acetate	NN	O	O
intoxication	NN	O	O
.	NN	O	O

Dexamethasone-induced	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
antimicrobial	NN	O	O
activity	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
macrophages	NN	O	I-cell_type
in	NN	O	O
vitro	NN	O	O
parallels	NN	O	O
observations	NN	O	O
that	NN	O	O
glucocorticoids	NN	O	O
render	NN	O	O
laboratory	NN	O	O
animals	NN	O	O
susceptible	NN	O	O
to	NN	O	O
listeriosis	NN	O	O
and	NN	O	O
aspergillosis	NN	O	O
by	NN	O	O
damaging	NN	O	O
resident	NN	O	O
macrophages	NN	O	B-cell_line
.	NN	O	O

Interleukin-2	NN	O	B-protein
(	NN	O	O
IL-2	NN	O	B-protein
)	NN	O	O
is	NN	O	O
a	NN	O	O
lymphokine	NN	O	B-protein
synthesized	NN	O	O
by	NN	O	O
some	NN	O	O
T-cells	NN	O	B-cell_type
following	NN	O	O
activation	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
6-	NN	O	O
and	NN	O	O
3-mo	NN	O	O
remissions	NN	O	O
of	NN	O	O
his	NN	O	O
leukemia	NN	O	O
following	NN	O	O
two	NN	O	O
courses	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
this	NN	O	O
monoclonal	NN	O	B-protein
antibody	NN	O	I-protein
directed	NN	O	O
toward	NN	O	O
this	NN	O	O
growth	NN	O	B-protein
factor	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

In	NN	O	O
intact	NN	O	O
cells	NN	O	O
,	NN	O	O
receptor	NN	O	O
number	NN	O	O
,	NN	O	O
affinity	NN	O	O
and	NN	O	O
activity	NN	O	O
can	NN	O	O
change	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
factors	NN	O	O
that	NN	O	O
bind	NN	O	O
to	NN	O	O
the	NN	O	O
receptor	NN	O	O
,	NN	O	O
or	NN	O	O
that	NN	O	O
act	NN	O	O
indirectly	NN	O	O
through	NN	O	O
ill-defined	NN	O	O
mechanisms	NN	O	O
which	NN	O	O
may	NN	O	O
include	NN	O	O
resumption	NN	O	O
or	NN	O	O
arrest	NN	O	O
of	NN	O	O
cell	NN	O	O
cycling	NN	O	O
and	NN	O	O
variations	NN	O	O
in	NN	O	O
intracellular	NN	O	O
calcium	NN	O	O
ion	NN	O	O
concentrations	NN	O	O
.	NN	O	O

-DOCSTART-	O

Thermodynamic	NN	O	O
values	NN	O	O
for	NN	O	O
the	NN	O	O
transition	NN	O	O
state	NN	O	O
were	NN	O	O
calculated	NN	O	O
from	NN	O	O
the	NN	O	O
rate	NN	O	O
constants	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
fit	NN	O	O
quite	NN	O	O
well	NN	O	O
with	NN	O	O
a	NN	O	O
two-step	NN	O	O
model	NN	O	O
[	NN	O	O
Ross	NN	O	O
&	NN	O	O
Subramanian	NN	O	O
(	NN	O	O
1981	NN	O	O
)	NN	O	O
Biochemistry	NN	O	O
20	NN	O	O
,	NN	O	O
3096-3102	NN	O	O
]	NN	O	O
proposed	NN	O	O
for	NN	O	O
ligand-protein	NN	O	O
interactions	NN	O	O
,	NN	O	O
which	NN	O	O
involves	NN	O	O
a	NN	O	O
partial	NN	O	O
immobilization	NN	O	O
of	NN	O	O
the	NN	O	O
reacting	NN	O	O
species	NN	O	O
governed	NN	O	O
by	NN	O	O
hydrophobic	NN	O	O
forces	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
stabilization	NN	O	O
of	NN	O	O
the	NN	O	O
complex	NN	O	O
by	NN	O	O
short-range	NN	O	O
interactions	NN	O	O
.	NN	O	O

Of	NN	O	O
biologic	NN	O	O
importance	NN	O	O
,	NN	O	O
these	NN	O	O
factors	NN	O	O
may	NN	O	O
refine	NN	O	O
further	NN	O	O
the	NN	O	O
characteristic	NN	O	O
features	NN	O	O
of	NN	O	O
clinically-determined	NN	O	O
prognostic	NN	O	O
groups	NN	O	O
.	NN	O	O

Current	NN	O	O
studies	NN	O	O
show	NN	O	O
a	NN	O	O
CNS	NN	O	O
relapse	NN	O	O
rate	NN	O	O
of	NN	O	O
5	NN	O	O
%	NN	O	O
in	NN	O	O
all	NN	O	O
prognostic	NN	O	O
groups	NN	O	O
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
400	NN	O	O
WORDS	NN	O	O
)	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
CLL	NN	O	B-cell_line
cells	NN	O	I-cell_line
presented	NN	O	O
the	NN	O	O
highest	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
glucocorticoids	NN	O	O
in	NN	O	O
PHA-stimulated	NN	O	B-cell_line
cell	NN	O	I-cell_line
cultures	NN	O	I-cell_line
.	NN	O	O

This	NN	O	O
process	NN	O	O
precedes	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
.	NN	O	O

Following	NN	O	O
immunoprecipitation	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
DM-labeled	NN	O	O
cytosol	NN	O	O
with	NN	O	O
immune	NN	O	O
serum	NN	O	O
,	NN	O	O
only	NN	O	O
the	NN	O	O
Mr	NN	O	O
90	NN	O	O
,	NN	O	O
000	NN	O	O
and	NN	O	O
78	NN	O	O
,	NN	O	O
000	NN	O	O
components	NN	O	O
were	NN	O	O
seen	NN	O	O
.	NN	O	O

The	NN	O	O
lesions	NN	O	O
included	NN	O	O
benign	NN	O	O
elements	NN	O	O
from	NN	O	O
66	NN	O	O
subcutaneous	NN	O	O
mastectomy	NN	O	O
specimens	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
simultaneous	NN	O	O
breast	NN	O	O
malignancy	NN	O	O
was	NN	O	O
documented	NN	O	O
,	NN	O	O
primary	NN	O	O
breast	NN	O	O
carcinomas	NN	O	O
from	NN	O	O
153	NN	O	O
mastectomy	NN	O	O
specimens	NN	O	O
,	NN	O	O
and	NN	O	O
47	NN	O	O
biopsies	NN	O	O
containing	NN	O	O
metastatic	NN	O	O
breast	NN	O	O
cancer	NN	O	O
.	NN	O	O

Cancer	NN	O	O
of	NN	O	O
the	NN	O	O
breast	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
tumor	NN	O	O
in	NN	O	O
females	NN	O	O
in	NN	O	O
Singapore	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
20.7	NN	O	O
per	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
per	NN	O	O
year	NN	O	O
(	NN	O	O
1977	NN	O	O
estimate	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
predicted	NN	O	O
to	NN	O	O
increase	NN	O	O
to	NN	O	O
29.8	NN	O	O
per	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
women	NN	O	O
per	NN	O	O
year	NN	O	O
by	NN	O	O
1995	NN	O	O
.	NN	O	O

Although	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
trend	NN	O	O
for	NN	O	O
ER	NN	O	B-protein
-positive	NN	O	O
tumors	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
low-grade	NN	O	O
lymphocytic	NN	O	O
infiltration	NN	O	O
,	NN	O	O
the	NN	O	O
difference	NN	O	O
was	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
positive	NN	O	O
correlation	NN	O	O
between	NN	O	O
the	NN	O	O
inflammatory	NN	O	O
infiltration	NN	O	O
and	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
HLA	NN	O	B-protein
class-I	NN	O	I-protein
antigens	NN	O	I-protein
on	NN	O	O
tumor	NN	O	B-cell_type
cell	NN	O	I-cell_type
s	NN	O	O
.	NN	O	O

Eleven	NN	O	O
patients	NN	O	O
with	NN	O	O
metastasized	NN	O	O
breast	NN	O	O
cancer	NN	O	O
received	NN	O	O
8	NN	O	O
intramuscular	NN	O	O
injections	NN	O	O
of	NN	O	O
6	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
units	NN	O	O
of	NN	O	O
human	NN	O	B-protein
fibroblast	NN	O	I-protein
interferon	NN	O	I-protein
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
40	NN	O	O
days	NN	O	O
.	NN	O	O

Lymphocytes	NN	O	B-cell_type
from	NN	O	O
patients	NN	O	O
with	NN	O	O
untreated	NN	O	O
adrenal	NN	O	O
insufficiency	NN	O	O
had	NN	O	O
fewer	NN	O	O
binding	NN	O	B-protein
sites	NN	O	I-protein
(	NN	O	O
3364	NN	O	O
+/-322	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
2-fold	NN	O	O
increase	NN	O	O
in	NN	O	O
binding	NN	O	O
affinity	NN	O	O
(	NN	O	O
5.4	NN	O	O
+/-	NN	O	O
0.9	NN	O	O
mM	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
long	NN	O	O
term	NN	O	O
glucocorticoid	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
,	NN	O	O
binding	NN	O	O
parameters	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
in	NN	O	O
patients	NN	O	O
before	NN	O	O
treatment	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
according	NN	O	O
to	NN	O	O
a	NN	O	O
common	NN	O	O
protocol	NN	O	O
.	NN	O	O

In	NN	O	O
previous	NN	O	O
work	NN	O	O
we	NN	O	O
showed	NN	O	O
that	NN	O	O
DAC	NN	O	O
is	NN	O	O
40-fold	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
DEX	NN	O	O
)	NN	O	O
in	NN	O	O
lysing	NN	O	O
leukemic	NN	O	B-cell_type
lymphoblasts	NN	O	I-cell_type
.	NN	O	O

Scatchard	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
binding	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
CVZ	NN	O	O
in	NN	O	O
glucocorticoid-sensitive	NN	O	B-cell_line
cells	NN	O	I-cell_line
revealed	NN	O	O
a	NN	O	O
curvilinear	NN	O	O
plot	NN	O	O
which	NN	O	O
resolved	NN	O	O
into	NN	O	O
high	NN	O	O
(	NN	O	O
0.4	NN	O	O
nM	NN	O	O
)	NN	O	O
and	NN	O	O
low	NN	O	O
(	NN	O	O
11	NN	O	O
nM	NN	O	O
)	NN	O	O
affinity	NN	O	O
components	NN	O	O
.	NN	O	O

This	NN	O	O
procedure	NN	O	O
which	NN	O	O
is	NN	O	O
simple	NN	O	O
,	NN	O	O
rapid	NN	O	O
,	NN	O	O
and	NN	O	O
highly	NN	O	O
reproducible	NN	O	O
is	NN	O	O
carried	NN	O	O
out	NN	O	O
using	NN	O	O
frozen	NN	O	O
samples	NN	O	O
(	NN	O	O
stable	NN	O	O
for	NN	O	O
many	NN	O	O
months	NN	O	O
)	NN	O	O
containing	NN	O	O
as	NN	O	O
few	NN	O	O
as	NN	O	O
1	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
7	NN	O	O
)	NN	O	O
cells	NN	O	O
.	NN	O	O

Overall	NN	O	O
relapse-free	NN	O	O
survival	NN	O	O
(	NN	O	O
RFS	NN	O	O
)	NN	O	O
was	NN	O	O
no	NN	O	O
different	NN	O	O
for	NN	O	O
those	NN	O	O
patients	NN	O	O
with	NN	O	O
receptors	NN	O	O
compared	NN	O	O
to	NN	O	O
those	NN	O	O
without	NN	O	O
them	NN	O	O
(	NN	O	O
REc	NN	O	B-protein
P	NN	O	O
=	NN	O	O
0.11	NN	O	O
,	NN	O	O
RPc	NN	O	O
P	NN	O	O
=	NN	O	O
0.7	NN	O	O
)	NN	O	O
.	NN	O	O

Clinical	NN	O	O
implications	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
human	NN	O	O
leukemia	NN	O	O
.	NN	O	O

Similar	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
can	NN	O	O
be	NN	O	O
detected	NN	O	O
in	NN	O	O
lymphoid	NN	O	B-cell_type
cells	NN	O	I-cell_type
from	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
lymphoblastic	NN	O	O
leukemia	NN	O	O
(	NN	O	O
ALL	NN	O	O
)	NN	O	O
.	NN	O	O

Recent	NN	O	O
observations	NN	O	O
that	NN	O	O
activated	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
may	NN	O	O
be	NN	O	O
sensitive	NN	O	O
to	NN	O	O
the	NN	O	O
lytic	NN	O	O
effects	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
suggest	NN	O	O
that	NN	O	O
under	NN	O	O
certain	NN	O	O
situations	NN	O	O
the	NN	O	O
elimination	NN	O	O
of	NN	O	O
selected	NN	O	O
subsets	NN	O	O
of	NN	O	O
cells	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
relevant	NN	O	O
mechanism	NN	O	O
of	NN	O	O
corticosteroid-mediated	NN	O	O
immunoregulation	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
heterodimer	NN	O	B-protein
Ku70/variant-Ku86	NN	O	I-protein
binds	NN	O	O
to	NN	O	O
DNA-ends	NN	O	B-DNA
,	NN	O	O
this	NN	O	O
altered	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
Ku	NN	O	B-protein
heterodimer	NN	O	I-protein
has	NN	O	O
a	NN	O	O
decreased	NN	O	O
ability	NN	O	O
to	NN	O	O
recruit	NN	O	O
the	NN	O	O
catalytic	NN	O	B-protein
component	NN	O	I-protein
of	NN	O	O
the	NN	O	O
complex	NN	O	O
,	NN	O	O
DNA-PK	NN	O	B-protein
(	NN	O	I-protein
CS	NN	O	I-protein
)	NN	O	I-protein
,	NN	O	O
which	NN	O	O
contributes	NN	O	O
to	NN	O	O
an	NN	O	O
absence	NN	O	O
of	NN	O	O
detectable	NN	O	O
DNA-PK	NN	O	O
activity	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
P-CREB	NN	O	B-protein
was	NN	O	O
evaluated	NN	O	O
following	NN	O	O
co-stimulation	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
PBMC	NN	O	I-cell_type
through	NN	O	O
the	NN	O	O
IL-2	NN	O	B-protein
and	NN	O	I-protein
CD2	NN	O	I-protein
or	NN	O	I-protein
CD3	NN	O	I-protein
receptors	NN	O	I-protein
.	NN	O	O

(	NN	O	O
Blood.	NN	O	O
2001	NN	O	O
;	NN	O	O
98	NN	O	O
:	NN	O	O
823-829	NN	O	O
)	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
rapid	NN	O	O
accumulation	NN	O	O
of	NN	O	O
antigen	NN	O	B-protein
within	NN	O	O
both	NN	O	O
superficial	NN	O	O
cervical	NN	O	O
lymph	NN	O	O
nodes	NN	O	O
(	NN	O	O
SCLN	NN	O	O
)	NN	O	O
and	NN	O	O
spleen	NN	O	O
was	NN	O	O
observed	NN	O	O
after	NN	O	O
30	NN	O	O
minutes	NN	O	O
.	NN	O	O

Interleukin	NN	O	B-protein
(	NN	O	I-protein
IL	NN	O	I-protein
)	NN	O	I-protein
-18	NN	O	I-protein
has	NN	O	O
been	NN	O	O
well	NN	O	O
characterized	NN	O	O
as	NN	O	O
a	NN	O	O
costimulatory	NN	O	B-protein
factor	NN	O	I-protein
for	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
IL-12-mediated	NN	O	B-protein
interferon	NN	O	I-protein
(	NN	O	I-protein
IFN	NN	O	I-protein
)	NN	O	I-protein
-gamma	NN	O	I-protein
production	NN	O	O
by	NN	O	O
T	NN	O	B-cell_type
helper	NN	O	I-cell_type
(	NN	O	I-cell_type
Th	NN	O	I-cell_type
)	NN	O	I-cell_type
1	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
but	NN	O	O
also	NN	O	O
can	NN	O	O
induce	NN	O	O
IL-4	NN	O	O
production	NN	O	O
and	NN	O	O
thus	NN	O	O
facilitate	NN	O	O
the	NN	O	O
differentiation	NN	O	O
of	NN	O	O
Th2	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Upon	NN	O	O
antigen	NN	O	O
stimulation	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
IL-12	NN	O	B-protein
,	NN	O	O
marked	NN	O	O
enhancement	NN	O	O
of	NN	O	O
IL-18Ralpha	NN	O	B-protein
expression	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Both	NN	O	O
IL-4	NN	O	B-cell_type
(	NN	O	I-cell_type
-/	NN	O	I-cell_type
)	NN	O	I-cell_type
-	NN	O	I-cell_type
and	NN	O	I-cell_type
signal	NN	O	I-cell_type
transducer	NN	O	I-cell_type
and	NN	O	I-cell_type
activator	NN	O	I-cell_type
of	NN	O	I-cell_type
transcription	NN	O	I-cell_type
(	NN	O	I-cell_type
Stat	NN	O	I-cell_type
)	NN	O	I-cell_type
6	NN	O	I-cell_type
(	NN	O	I-cell_type
-/	NN	O	I-cell_type
)	NN	O	I-cell_type
-	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
expressed	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
IL-18Ralpha	NN	O	B-protein
after	NN	O	O
TCR	NN	O	O
stimulation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
biomechanical	NN	O	O
strain	NN	O	O
regulates	NN	O	O
macrophage	NN	O	O
phenotype	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Human	NN	O	B-cell_type
monocyte/macrophages	NN	O	I-cell_type
or	NN	O	O
THP-1	NN	O	B-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
cultured	NN	O	O
in	NN	O	O
a	NN	O	O
device	NN	O	O
that	NN	O	O
imposes	NN	O	O
uniform	NN	O	O
biaxial	NN	O	O
cyclic	NN	O	O
1-Hz	NN	O	O
strains	NN	O	O
of	NN	O	O
0	NN	O	O
%	NN	O	O
,	NN	O	O
1	NN	O	O
%	NN	O	O
,	NN	O	O
2	NN	O	O
%	NN	O	O
,	NN	O	O
or	NN	O	O
3	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
SRA	NN	O	B-protein
expression	NN	O	O
was	NN	O	O
analyzed	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
:	NN	O	O
High	NN	O	O
glucose	NN	O	O
induced	NN	O	O
mesothelial	NN	O	O
MCP-1	NN	O	B-protein
expression	NN	O	O
partly	NN	O	O
via	NN	O	O
the	NN	O	O
tyrosine	NN	O	O
kinase-	NN	O	O
AP-1	NN	O	B-protein
pathway	NN	O	O
.	NN	O	O

This	NN	O	O
alone	NN	O	O
was	NN	O	O
sufficient	NN	O	O
to	NN	O	O
generate	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
CD86	NN	O	B-protein
levels	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
of	NN	O	O
distinct	NN	O	O
signal	NN	O	O
transducer	NN	O	O
requirements	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
added	NN	O	O
consequences	NN	O	O
of	NN	O	O
cross-talk	NN	O	O
,	NN	O	O
offers	NN	O	O
an	NN	O	O
explanation	NN	O	O
for	NN	O	O
variable	NN	O	O
modulation	NN	O	O
of	NN	O	O
costimulatory	NN	O	O
molecule	NN	O	O
expression	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
diverse	NN	O	O
physiological	NN	O	O
stimuli	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
no	NN	O	O
changes	NN	O	O
are	NN	O	O
seen	NN	O	O
in	NN	O	O
explants	NN	O	O
cultured	NN	O	O
with	NN	O	O
IFN-alpha	NN	O	B-protein
alone	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
enhanced	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
STAT1	NN	O	B-protein
,	NN	O	O
STAT3	NN	O	B-protein
,	NN	O	O
and	NN	O	O
Fyn	NN	O	B-protein
,	NN	O	I-protein
a	NN	O	I-protein
Src	NN	O	I-protein
homology	NN	O	I-protein
tyrosine	NN	O	I-protein
kinase	NN	O	I-protein
,	NN	O	O
which	NN	O	O
interacts	NN	O	O
with	NN	O	O
both	NN	O	O
TCR	NN	O	O
and	NN	O	O
IFN-alpha	NN	O	O
signal	NN	O	O
components	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
cAMP	NN	O	O
inhibits	NN	O	O
LPS-stimulated	NN	O	O
TNF-alpha	NN	O	B-protein
production	NN	O	O
through	NN	O	O
a	NN	O	O
posttranscriptional	NN	O	O
mechanism	NN	O	O
that	NN	O	O
is	NN	O	O
independent	NN	O	O
of	NN	O	O
endogenous	NN	O	O
IL-10	NN	O	B-protein
.	NN	O	O

The	NN	O	O
smallest	NN	O	O
unit	NN	O	O
of	NN	O	O
bacterial	NN	O	O
peptidoglycans	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
endowed	NN	O	O
with	NN	O	O
biological	NN	O	O
activities	NN	O	O
is	NN	O	O
muramyl	NN	O	O
dipeptide	NN	O	O
(	NN	O	O
MDP	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
ex	NN	O	O
vivo	NN	O	O
expression	NN	O	O
of	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
was	NN	O	O
higher	NN	O	O
in	NN	O	O
PBMCs	NN	O	B-cell_type
of	NN	O	O
controls	NN	O	O
than	NN	O	O
of	NN	O	O
trauma	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
An	NN	O	O
imbalance	NN	O	O
between	NN	O	O
endothelin	NN	O	O
and	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
levels	NN	O	O
results	NN	O	O
in	NN	O	O
failure	NN	O	O
of	NN	O	O
the	NN	O	O
hepatic	NN	O	O
microcirculation	NN	O	O
at	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
reperfusion	NN	O	O
.	NN	O	O

We	NN	O	O
analyzed	NN	O	O
the	NN	O	O
mechanism	NN	O	O
that	NN	O	O
causes	NN	O	O
suppression	NN	O	O
of	NN	O	O
IL-12	NN	O	B-DNA
p40	NN	O	I-DNA
gene	NN	O	I-DNA
induction	NN	O	O
during	NN	O	O
Plasmodium	NN	O	O
berghei	NN	O	O
infection	NN	O	O
.	NN	O	O

The	NN	O	O
GATA	NN	O	B-protein
factor	NN	O	I-protein
Pannier	NN	O	I-protein
(	NN	O	O
Pnr	NN	O	B-protein
)	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
eye	NN	O	O
and	NN	O	O
heart	NN	O	O
development	NN	O	O
in	NN	O	O
Drosophila	NN	O	O
.	NN	O	O

TRAIL/Apo2L	NN	O	B-protein
potently	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
MM	NN	O	B-cell_type
cells	NN	O	I-cell_type
from	NN	O	O
patients	NN	O	O
and	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
MM	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
including	NN	O	O
cells	NN	O	O
sensitive	NN	O	O
or	NN	O	O
resistant	NN	O	O
to	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
Dex	NN	O	O
)	NN	O	O
,	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
Dox	NN	O	O
)	NN	O	O
,	NN	O	O
melphalan	NN	O	O
,	NN	O	O
and	NN	O	O
mitoxantrone	NN	O	O
.	NN	O	O

Galectin-10	NN	O	B-protein
(	NN	O	O
gal-10	NN	O	B-protein
,	NN	O	O
also	NN	O	O
known	NN	O	O
as	NN	O	O
Charcot-Leyden	NN	O	B-protein
crystal	NN	O	I-protein
protein	NN	O	I-protein
)	NN	O	O
is	NN	O	O
a	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
galectin	NN	O	B-protein
family	NN	O	I-protein
of	NN	O	O
beta-galactoside	NN	O	B-protein
binding	NN	O	I-protein
proteins	NN	O	I-protein
that	NN	O	O
is	NN	O	O
expressed	NN	O	O
uniquely	NN	O	O
in	NN	O	O
eosinophilic	NN	O	B-cell_type
and	NN	O	I-cell_type
basophilic	NN	O	I-cell_type
leukocytes	NN	O	I-cell_type
.	NN	O	O

Mammary	NN	O	O
development	NN	O	O
depends	NN	O	O
on	NN	O	O
branching	NN	O	O
morphogenesis	NN	O	O
,	NN	O	O
namely	NN	O	O
the	NN	O	O
bifurcation	NN	O	O
and	NN	O	O
extension	NN	O	O
of	NN	O	O
ductal	NN	O	O
growth	NN	O	O
points	NN	O	O
(	NN	O	O
end	NN	O	O
buds	NN	O	O
)	NN	O	O
and	NN	O	O
secretory	NN	O	O
lobules	NN	O	O
into	NN	O	O
a	NN	O	O
more	NN	O	O
or	NN	O	O
less	NN	O	O
fatty	NN	O	O
stroma	NN	O	O
.	NN	O	O

Because	NN	O	O
breast	NN	O	O
carcinomas	NN	O	O
are	NN	O	O
overwhelmingly	NN	O	O
ductal	NN	O	O
in	NN	O	O
origin	NN	O	O
,	NN	O	O
this	NN	O	O
review	NN	O	O
focuses	NN	O	O
on	NN	O	O
stromal	NN	O	O
influences	NN	O	O
guiding	NN	O	O
postnatal	NN	O	O
ductal	NN	O	O
development	NN	O	O
and	NN	O	O
there	NN	O	O
is	NN	O	O
only	NN	O	O
the	NN	O	O
briefest	NN	O	O
account	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
embryonic	NN	O	O
stroma	NN	O	O
(	NN	O	O
mesenchyme	NN	O	O
)	NN	O	O
.	NN	O	O

Adipophilin	NN	O	B-protein
,	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
lipid	NN	O	O
accumulation	NN	O	O
initially	NN	O	O
described	NN	O	O
in	NN	O	O
adipocytes	NN	O	B-cell_type
,	NN	O	O
was	NN	O	O
recently	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
induced	NN	O	O
in	NN	O	O
macrophage	NN	O	B-cell_type
foam	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Enzymatically	NN	O	B-protein
modified	NN	O	I-protein
low-density	NN	O	I-protein
lipoprotein	NN	O	I-protein
(	NN	O	O
E-LDL	NN	O	B-protein
)	NN	O	O
induces	NN	O	O
rapid	NN	O	O
foam	NN	O	O
cell	NN	O	O
formation	NN	O	O
in	NN	O	O
monocytes	NN	O	B-cell_type
and	NN	O	O
upregulates	NN	O	O
adipophilin	NN	O	B-protein
mRNA	NN	O	O
and	NN	O	O
protein	NN	O	O
within	NN	O	O
2	NN	O	O
h	NN	O	O
of	NN	O	O
incubation	NN	O	O
.	NN	O	O

Unexpectedly	NN	O	O
,	NN	O	O
these	NN	O	O
transcripts	NN	O	O
initiate	NN	O	O
from	NN	O	O
promoter	NN	O	B-DNA
III	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
CIITA	NN	O	B-DNA
gene	NN	O	I-DNA
,	NN	O	O
a	NN	O	O
promoter	NN	O	O
that	NN	O	O
is	NN	O	O
mainly	NN	O	O
used	NN	O	O
constitutively	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

Calcineurin	NN	O	B-protein
,	NN	O	O
a	NN	O	O
Ca	NN	O	B-protein
(	NN	O	I-protein
2+	NN	O	I-protein
)	NN	O	I-protein
/calmodulin-dependent	NN	O	I-protein
Ser/Thr	NN	O	I-protein
phosphatase	NN	O	I-protein
(	NN	O	I-protein
protein	NN	O	I-protein
phosphatase	NN	O	I-protein
2B	NN	O	I-protein
)	NN	O	I-protein
,	NN	O	O
plays	NN	O	O
a	NN	O	O
critical	NN	O	O
role	NN	O	O
in	NN	O	O
IL-2	NN	O	O
production	NN	O	O
during	NN	O	O
T	NN	O	O
cell	NN	O	O
activation	NN	O	O
.	NN	O	O

Sulfapyridine	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
dendritic	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
(	NN	O	O
auto	NN	O	O
)	NN	O	O
immunity	NN	O	O
,	NN	O	O
inhibition	NN	O	O
of	NN	O	O
their	NN	O	O
maturation	NN	O	O
might	NN	O	O
provide	NN	O	O
a	NN	O	O
target	NN	O	O
for	NN	O	O
further	NN	O	O
optimization	NN	O	O
of	NN	O	O
sulfasalazine	NN	O	O
therapy	NN	O	O
.	NN	O	O

This	NN	O	O
defect	NN	O	O
prevents	NN	O	O
the	NN	O	O
proteolytic	NN	O	O
processing	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
production	NN	O	O
and	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
nuclear	NN	O	I-protein
factor-kappaB	NN	O	I-protein
(	NN	O	O
NF-kappaB	NN	O	B-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
plays	NN	O	O
important	NN	O	O
roles	NN	O	O
in	NN	O	O
immune	NN	O	O
and	NN	O	O
inflammatory	NN	O	O
responses	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
increases	NN	O	O
the	NN	O	O
susceptibility	NN	O	O
of	NN	O	O
the	NN	O	O
affected	NN	O	O
cells	NN	O	O
to	NN	O	O
apoptosis	NN	O	O
induced	NN	O	O
by	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor-alpha	NN	O	I-protein
(	NN	O	O
TNF-alpha	NN	O	B-protein
)	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
were	NN	O	O
obtained	NN	O	O
at	NN	O	O
weekly	NN	O	O
intervals	NN	O	O
.	NN	O	O

Troglitazone	NN	O	O
,	NN	O	O
a	NN	O	O
PPARgamma	NN	O	B-protein
ligand	NN	O	O
,	NN	O	O
dramatically	NN	O	O
attenuated	NN	O	O
the	NN	O	O
PMA-induced	NN	O	O
osteopontin	NN	O	O
expression	NN	O	O
.	NN	O	O

Transient	NN	O	O
transfection	NN	O	O
assays	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
osteopontin	NN	O	I-DNA
promoter/luciferase	NN	O	I-DNA
construct	NN	O	I-DNA
which	NN	O	O
contains	NN	O	O
a	NN	O	O
5'-flanking	NN	O	B-DNA
region	NN	O	I-DNA
between	NN	O	O
-1500	NN	O	O
and	NN	O	O
+87	NN	O	O
relative	NN	O	O
to	NN	O	O
the	NN	O	O
transcription	NN	O	B-DNA
start	NN	O	I-DNA
site	NN	O	I-DNA
demonstrate	NN	O	O
that	NN	O	O
either	NN	O	O
treatment	NN	O	O
with	NN	O	O
troglitazone	NN	O	O
or	NN	O	O
cotransfection	NN	O	O
of	NN	O	O
PPARgamma	NN	O	B-DNA
expression	NN	O	I-DNA
vector	NN	O	I-DNA
inhibits	NN	O	O
osteopontin	NN	O	O
promoter	NN	O	O
activity	NN	O	O
.	NN	O	O

Directed	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
accessibility	NN	O	O
of	NN	O	O
V	NN	O	B-DNA
,	NN	O	I-DNA
D	NN	O	I-DNA
,	NN	O	I-DNA
and	NN	O	I-DNA
J	NN	O	I-DNA
gene	NN	O	I-DNA
segments	NN	O	I-DNA
target	NN	O	O
the	NN	O	O
recombinase	NN	O	B-protein
to	NN	O	O
specific	NN	O	O
Ag	NN	O	B-DNA
receptor	NN	O	I-DNA
loci	NN	O	I-DNA
.	NN	O	O

Nonetheless	NN	O	O
,	NN	O	O
we	NN	O	O
now	NN	O	O
show	NN	O	O
that	NN	O	O
specific	NN	O	O
repression	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
inhibits	NN	O	O
germline	NN	O	O
transcription	NN	O	O
and	NN	O	O
recombination	NN	O	O
of	NN	O	O
Iglambda	NN	O	B-DNA
gene	NN	O	I-DNA
segments	NN	O	I-DNA
in	NN	O	O
precursor	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Molecular	NN	O	O
analyses	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
block	NN	O	O
in	NN	O	O
NF-kappaB	NN	O	B-protein
impairs	NN	O	O
Iglambda	NN	O	O
rearrangement	NN	O	O
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
recombinase	NN	O	B-protein
accessibility	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
,	NN	O	O
it	NN	O	O
appears	NN	O	O
that	NN	O	O
IL-12	NN	O	B-protein
/	NN	O	O
STAT4	NN	O	B-protein
serves	NN	O	O
two	NN	O	O
essential	NN	O	O
functions	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
TH1	NN	O	B-cell_type
cells	NN	O	I-cell_type
:	NN	O	O
as	NN	O	O
growth	NN	O	B-protein
signal	NN	O	I-protein
,	NN	O	O
inducing	NN	O	O
survival	NN	O	O
and	NN	O	O
cell	NN	O	O
division	NN	O	O
;	NN	O	O
and	NN	O	O
as	NN	O	O
trans-activator	NN	O	B-protein
,	NN	O	O
prolonging	NN	O	O
IFN-gamma	NN	O	B-protein
synthesis	NN	O	O
through	NN	O	O
a	NN	O	O
genetic	NN	O	O
interaction	NN	O	O
with	NN	O	O
the	NN	O	O
coactivator	NN	O	B-protein
,	NN	O	O
CREB-binding	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

To	NN	O	O
determine	NN	O	O
the	NN	O	O
roles	NN	O	O
of	NN	O	O
the	NN	O	O
phosphotyrosine	NN	O	B-protein
binding	NN	O	I-protein
adaptors	NN	O	I-protein
in	NN	O	O
Th2	NN	O	O
differentiation	NN	O	O
,	NN	O	O
we	NN	O	O
prepared	NN	O	O
a	NN	O	O
retrovirus	NN	O	O
containing	NN	O	O
a	NN	O	O
mutant	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-protein
(	NN	O	I-protein
h	NN	O	I-protein
)	NN	O	I-protein
IL-4R	NN	O	I-protein
alpha-chain	NN	O	I-protein
,	NN	O	O
Y497F	NN	O	B-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
unable	NN	O	O
to	NN	O	O
recruit	NN	O	O
these	NN	O	O
adaptors	NN	O	O
.	NN	O	O

Both	NN	O	O
WT	NN	O	B-protein
and	NN	O	I-protein
Y497F	NN	O	I-protein
hIL-4Ralpha	NN	O	I-protein
lose	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
drive	NN	O	O
Th2	NN	O	O
differentiation	NN	O	O
and	NN	O	O
cell	NN	O	O
expansion	NN	O	O
in	NN	O	O
Stat6-knockout	NN	O	B-cell_type
CD4	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
HIV-infected	NN	O	O
individuals	NN	O	O
dysregulation	NN	O	O
of	NN	O	O
the	NN	O	O
immune	NN	O	O
system	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
severe	NN	O	O
disorders	NN	O	O
of	NN	O	O
the	NN	O	O
cytokine	NN	O	O
network	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
TGF-beta	NN	O	B-protein
(	NN	O	I-protein
1	NN	O	I-protein
)	NN	O	I-protein
interferes	NN	O	O
directly	NN	O	O
with	NN	O	O
TPO	NN	O	B-protein
-induced	NN	O	O
signal	NN	O	O
transduction	NN	O	O
in	NN	O	O
hematopoietic	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
we	NN	O	O
compared	NN	O	O
the	NN	O	O
regulatory	NN	O	O
effects	NN	O	O
in	NN	O	O
the	NN	O	O
TPO	NN	O	B-protein
-responsive	NN	O	O
cell	NN	O	O
lines	NN	O	O
Mo-7e	NN	O	O
and	NN	O	O
HEL	NN	O	O
.	NN	O	O

As	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
Western	NN	O	O
blotting	NN	O	O
,	NN	O	O
TGF-beta1	NN	O	B-protein
reduced	NN	O	O
the	NN	O	O
TPO	NN	O	B-protein
-stimulated	NN	O	O
ERK1	NN	O	B-protein
/	NN	O	O
ERK2	NN	O	B-protein
and	NN	O	O
STAT5	NN	O	O
phosphorylation	NN	O	O
in	NN	O	O
Mo-7e	NN	O	B-cell_line
and	NN	O	I-cell_line
HEL	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Although	NN	O	O
STAT3	NN	O	B-protein
also	NN	O	O
was	NN	O	O
activated	NN	O	O
by	NN	O	O
TPO	NN	O	B-protein
,	NN	O	O
STAT3	NN	O	B-protein
activation	NN	O	O
remained	NN	O	O
unaltered	NN	O	O
by	NN	O	O
TGF-beta1	NN	O	B-protein
.	NN	O	O

No	NN	O	O
alterations	NN	O	O
of	NN	O	O
thymocyte	NN	O	B-cell_type
subpopulations	NN	O	I-cell_type
were	NN	O	O
seen	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
CD4+	NN	O	B-cell_type
CD8+	NN	O	I-cell_type
thymocytes	NN	O	I-cell_type
after	NN	O	O
administration	NN	O	O
of	NN	O	O
androgens	NN	O	O
depend	NN	O	O
on	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
functional	NN	O	O
androgen	NN	O	B-protein
receptors	NN	O	I-protein
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
androgens	NN	O	O
indirectly	NN	O	O
accelerate	NN	O	O
thymocyte	NN	O	B-cell_type
apoptosis	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Through	NN	O	O
primer	NN	O	O
extension	NN	O	O
analysis	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
transcription	NN	O	O
of	NN	O	O
the	NN	O	O
h2B4	NN	O	B-DNA
gene	NN	O	I-DNA
initiates	NN	O	O
at	NN	O	O
multiple	NN	O	O
start	NN	O	O
sites	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
identified	NN	O	O
a	NN	O	O
functional	NN	O	O
AP-1	NN	O	B-DNA
site	NN	O	I-DNA
that	NN	O	O
lies	NN	O	O
between	NN	O	O
(	NN	O	O
-106	NN	O	O
to	NN	O	O
-100	NN	O	O
)	NN	O	O
through	NN	O	O
transient	NN	O	O
transfection	NN	O	O
analysis	NN	O	O
in	NN	O	O
YT	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
a	NN	O	O
human	NN	O	B-cell_line
NK	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
.	NN	O	O

High	NN	O	O
constitutive	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
IFNgamma-inducible	NN	O	B-DNA
genes	NN	O	I-DNA
,	NN	O	O
IFN-stimulated	NN	O	B-protein
gene	NN	O	I-protein
factor	NN	O	I-protein
3	NN	O	I-protein
gamma	NN	O	I-protein
subunit	NN	O	I-protein
(	NN	O	O
ISGF3gamma	NN	O	B-protein
)	NN	O	O
,	NN	O	O
IFN	NN	O	B-protein
regulatory	NN	O	I-protein
factor-1	NN	O	I-protein
(	NN	O	O
IRF-1	NN	O	B-protein
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
cyclin-dependent	NN	O	B-protein
kinase	NN	O	I-protein
inhibitor	NN	O	I-protein
p21	NN	O	I-protein
(	NN	O	O
WAF1	NN	O	B-protein
)	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
FANCC	NN	O	B-protein
mutant	NN	O	O
B	NN	O	B-cell_type
lymphoblasts	NN	O	I-cell_type
,	NN	O	O
low-density	NN	O	B-cell_type
bone	NN	O	I-cell_type
marrow	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
murine	NN	O	B-cell_type
embryonic	NN	O	I-cell_type
fibroblasts	NN	O	I-cell_type
.	NN	O	O

Levels	NN	O	O
of	NN	O	O
the	NN	O	O
IFNgamma	NN	O	B-protein
-inducible	NN	O	O
factor	NN	O	O
IFN	NN	O	B-protein
consensus	NN	O	I-protein
sequence	NN	O	I-protein
binding	NN	O	I-protein
protein	NN	O	I-protein
(	NN	O	O
ICSBP	NN	O	B-protein
)	NN	O	O
,	NN	O	O
a	NN	O	O
negative	NN	O	B-protein
trans-acting	NN	O	I-protein
regulator	NN	O	I-protein
of	NN	O	O
some	NN	O	O
IFNgamma-inducible	NN	O	B-DNA
genes	NN	O	I-DNA
,	NN	O	O
were	NN	O	O
quantified	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
when	NN	O	O
D609	NN	O	O
(	NN	O	O
50	NN	O	O
mg/kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
mice	NN	O	O
10	NN	O	O
min	NN	O	O
prior	NN	O	O
to	NN	O	O
total	NN	O	O
body	NN	O	O
IR	NN	O	O
(	NN	O	O
6.5	NN	O	O
and	NN	O	O
8.5	NN	O	O
Gy	NN	O	O
)	NN	O	O
,	NN	O	O
it	NN	O	O
protected	NN	O	O
the	NN	O	O
mice	NN	O	O
from	NN	O	O
IR-induced	NN	O	O
lethality	NN	O	O
.	NN	O	O

The	NN	O	O
immunosuppressive	NN	O	O
effects	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
arise	NN	O	O
largely	NN	O	O
by	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cytokine	NN	O	O
gene	NN	O	O
expression	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
ascribed	NN	O	O
to	NN	O	O
interference	NN	O	O
between	NN	O	O
the	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
and	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
such	NN	O	O
as	NN	O	O
AP-1	NN	O	B-protein
and	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
as	NN	O	O
well	NN	O	O
as	NN	O	O
by	NN	O	O
competition	NN	O	O
for	NN	O	O
common	NN	O	O
coactivators	NN	O	O
.	NN	O	O

This	NN	O	O
could	NN	O	O
be	NN	O	O
accounted	NN	O	O
for	NN	O	O
by	NN	O	O
GILZ	NN	O	B-protein
-mediated	NN	O	O
inhibition	NN	O	O
of	NN	O	O
Egr-2	NN	O	B-protein
and	NN	O	O
Egr-3	NN	O	B-protein
,	NN	O	O
NFAT/AP-1	NN	O	B-protein
-inducible	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
that	NN	O	O
bind	NN	O	O
a	NN	O	O
regulatory	NN	O	B-DNA
element	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
FasL	NN	O	B-DNA
promoter	NN	O	I-DNA
and	NN	O	O
up-regulate	NN	O	O
FasL	NN	O	O
expression	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
Smad7	NN	O	B-protein
substantially	NN	O	O
abrogates	NN	O	O
the	NN	O	O
synergistic	NN	O	O
effect	NN	O	O
of	NN	O	O
Smad3/4	NN	O	B-protein
on	NN	O	O
GLalpha	NN	O	B-DNA
promoter	NN	O	I-DNA
activity	NN	O	O
.	NN	O	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
human	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
constitutively	NN	O	O
express	NN	O	O
the	NN	O	O
translesion	NN	O	B-protein
pol	NN	O	I-protein
zeta	NN	O	I-protein
,	NN	O	O
which	NN	O	O
effectively	NN	O	O
extends	NN	O	O
DNA	NN	O	O
past	NN	O	O
mismatched	NN	O	O
bases	NN	O	O
(	NN	O	O
mispair	NN	O	O
extender	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
pol	NN	O	B-protein
eta	NN	O	I-protein
,	NN	O	O
which	NN	O	O
bypasses	NN	O	O
DNA	NN	O	O
lesions	NN	O	O
in	NN	O	O
an	NN	O	O
error-free	NN	O	O
fashion	NN	O	O
.	NN	O	O

-DOCSTART-	O

DESIGN	NN	O	O
:	NN	O	O
Prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
laboratory	NN	O	O
study	NN	O	O
.	NN	O	O

C57Bl/6	NN	O	O
mice	NN	O	O
produce	NN	O	O
a	NN	O	O
CD4+	NN	O	O
Th1	NN	O	O
(	NN	O	O
interferon	NN	O	O
[	NN	O	O
IFN	NN	O	O
]	NN	O	O
gamma+	NN	O	O
)	NN	O	O
response	NN	O	O
,	NN	O	O
express	NN	O	O
IA	NN	O	B-protein
(	NN	O	I-protein
b	NN	O	I-protein
)	NN	O	I-protein
but	NN	O	O
no	NN	O	O
IE	NN	O	B-protein
,	NN	O	O
and	NN	O	O
are	NN	O	O
atherosclerosis-prone	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
NF-kappaB	NN	O	O
response	NN	O	O
was	NN	O	O
blocked	NN	O	O
with	NN	O	O
a	NN	O	O
synthetic	NN	O	O
peptide	NN	O	O
corresponding	NN	O	O
to	NN	O	O
the	NN	O	O
putative	NN	O	B-protein
ligand-binding	NN	O	I-protein
domain	NN	O	I-protein
of	NN	O	O
RAGE	NN	O	B-protein
,	NN	O	O
with	NN	O	O
anti-	NN	O	O
RAGE	NN	O	B-protein
antiserum	NN	O	O
,	NN	O	O
and	NN	O	O
by	NN	O	O
coexpression	NN	O	O
of	NN	O	O
truncated	NN	O	B-protein
receptors	NN	O	I-protein
lacking	NN	O	O
the	NN	O	O
intracellular	NN	O	B-protein
domain	NN	O	I-protein
.	NN	O	O

RAGE	NN	O	B-protein
-mediated	NN	O	O
NF-kappaB	NN	O	O
activation	NN	O	O
was	NN	O	O
suppressed	NN	O	O
by	NN	O	O
the	NN	O	O
selective	NN	O	O
p38	NN	O	B-protein
MAPK	NN	O	I-protein
inhibitor	NN	O	O
SB203580	NN	O	O
and	NN	O	O
by	NN	O	O
coexpression	NN	O	O
of	NN	O	O
a	NN	O	O
kinase-dead	NN	O	O
p38	NN	O	O
dominant-negative	NN	O	O
mutant	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
p38	NN	O	B-protein
MAPK	NN	O	I-protein
activation	NN	O	O
mediates	NN	O	O
RAGE	NN	O	B-protein
-induced	NN	O	O
NF-kappaB	NN	O	B-protein
-dependent	NN	O	O
secretion	NN	O	O
of	NN	O	O
proinflammatory	NN	O	B-protein
cytokines	NN	O	I-protein
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
accelerated	NN	O	O
inflammation	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
cellular	NN	O	O
activation	NN	O	O
induced	NN	O	O
by	NN	O	O
this	NN	O	O
receptor	NN	O	O
.	NN	O	O

Antigen-receptor	NN	O	O
cross-linking	NN	O	O
and	NN	O	O
lipopolysaccharide	NN	O	O
trigger	NN	O	O
distinct	NN	O	O
phosphoinositide	NN	O	B-protein
3-kinase	NN	O	I-protein
-dependent	NN	O	O
pathways	NN	O	O
to	NN	O	O
NF-kappa	NN	O	O
B	NN	O	O
activation	NN	O	O
in	NN	O	O
primary	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Nuclear	NN	O	B-protein
NF-kappaB	NN	O	I-protein
is	NN	O	O
induced	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
engagement	NN	O	O
of	NN	O	O
either	NN	O	O
the	NN	O	O
BCR	NN	O	B-protein
or	NN	O	O
CD40	NN	O	B-protein
or	NN	O	O
by	NN	O	O
stimulation	NN	O	O
with	NN	O	O
lipopolysaccharide	NN	O	O
(	NN	O	O
LPS	NN	O	O
)	NN	O	O
.	NN	O	O

Using	NN	O	O
the	NN	O	O
specific	NN	O	O
pharmacological	NN	O	O
inhibitors	NN	O	O
of	NN	O	O
PI	NN	O	B-protein
3-kinase	NN	O	I-protein
,	NN	O	O
Wortmannin	NN	O	O
and	NN	O	O
LY294002	NN	O	O
,	NN	O	O
we	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
PI	NN	O	B-protein
3-kinase	NN	O	I-protein
activity	NN	O	O
is	NN	O	O
vital	NN	O	O
for	NN	O	O
BCR	NN	O	B-protein
-induced	NN	O	O
NF-kappaB	NN	O	B-protein
DNA-binding	NN	O	O
activity	NN	O	O
.	NN	O	O

Similar	NN	O	O
analyses	NN	O	O
reveal	NN	O	O
that	NN	O	O
PI	NN	O	B-protein
3-kinase	NN	O	I-protein
is	NN	O	O
also	NN	O	O
critical	NN	O	O
in	NN	O	O
triggering	NN	O	O
NF-kappaB	NN	O	B-protein
DNA-binding	NN	O	O
activity	NN	O	O
and	NN	O	O
IkappaBalpha	NN	O	B-protein
degradation	NN	O	O
following	NN	O	O
LPS	NN	O	O
stimulation	NN	O	O
.	NN	O	O

The	NN	O	O
four	NN	O	O
calcium-regulated	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
of	NN	O	O
the	NN	O	O
NFAT	NN	O	B-protein
family	NN	O	I-protein
act	NN	O	O
synergistically	NN	O	O
with	NN	O	O
AP-1	NN	O	B-protein
(	NN	O	I-protein
Fos/Jun	NN	O	I-protein
)	NN	O	I-protein
proteins	NN	O	I-protein
on	NN	O	O
composite	NN	O	O
DNA	NN	O	O
elements	NN	O	O
which	NN	O	O
contain	NN	O	O
adjacent	NN	O	O
NFAT	NN	O	B-DNA
and	NN	O	I-DNA
AP-1	NN	O	I-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
,	NN	O	O
where	NN	O	O
they	NN	O	O
form	NN	O	O
highly	NN	O	O
stable	NN	O	O
ternary	NN	O	O
complexes	NN	O	O
to	NN	O	O
regulate	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
diverse	NN	O	O
inducible	NN	O	O
genes	NN	O	O
.	NN	O	O

Nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
NF-kappaB/Rel	NN	O	B-protein
proteins	NN	O	I-protein
coincided	NN	O	O
with	NN	O	O
IkappaBalpha	NN	O	O
degradation	NN	O	O
.	NN	O	O

(	NN	O	O
Blood.	NN	O	O
2001	NN	O	O
;	NN	O	O
97	NN	O	O
:	NN	O	O
3941-3950	NN	O	O
)	NN	O	O

A	NN	O	O
constitutive	NN	O	O
activation	NN	O	O
of	NN	O	O
STAT	NN	O	B-protein
factors	NN	O	I-protein
could	NN	O	O
explain	NN	O	O
the	NN	O	O
increased	NN	O	O
proliferation	NN	O	O
of	NN	O	O
P.	NN	O	B-cell_type
vera	NN	O	I-cell_type
cells	NN	O	I-cell_type
even	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
growth	NN	O	O
factor	NN	O	O
stimulation	NN	O	O
.	NN	O	O

BAP/TFII-I	NN	O	B-protein
,	NN	O	O
a	NN	O	O
protein	NN	O	O
implicated	NN	O	O
in	NN	O	O
transcriptional	NN	O	O
regulation	NN	O	O
,	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
Btk	NN	O	B-protein
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
is	NN	O	O
transiently	NN	O	O
phosphorylated	NN	O	O
on	NN	O	O
tyrosine	NN	O	O
following	NN	O	O
B	NN	O	B-cell_type
cell	NN	O	I-cell_type
receptor	NN	O	O
engagement	NN	O	O
.	NN	O	O

Stem	NN	O	B-protein
cell	NN	O	I-protein
factor	NN	O	I-protein
and	NN	O	O
interleukin-3	NN	O	B-protein
induce	NN	O	O
stepwise	NN	O	O
generation	NN	O	O
of	NN	O	O
erythroid	NN	O	B-cell_type
precursor	NN	O	I-cell_type
cells	NN	O	I-cell_type
from	NN	O	O
a	NN	O	O
basic	NN	O	O
fibroblast	NN	O	B-protein
growth	NN	O	I-protein
factor	NN	O	I-protein
-dependent	NN	O	O
hematopoietic	NN	O	B-cell_line
stem	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
,	NN	O	I-cell_line
A-6	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
quantitative	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
erythroid	NN	O	B-cell_type
precursor	NN	O	I-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
newly	NN	O	O
produced	NN	O	O
from	NN	O	O
the	NN	O	O
immature	NN	O	B-cell_type
myeloid	NN	O	I-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
cultivation	NN	O	O
with	NN	O	O
IL-3	NN	O	B-protein
.	NN	O	O

Our	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
BMI-1	NN	O	B-protein
and	NN	O	O
EZH2	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
mature	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
is	NN	O	O
mutually	NN	O	O
exclusive	NN	O	O
and	NN	O	O
linked	NN	O	O
to	NN	O	O
proliferation	NN	O	O
status	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
this	NN	O	O
pattern	NN	O	O
is	NN	O	O
not	NN	O	O
yet	NN	O	O
established	NN	O	O
in	NN	O	O
thymocytes	NN	O	B-cell_type
of	NN	O	O
the	NN	O	O
cortex	NN	O	O
and	NN	O	O
medulla	NN	O	O
.	NN	O	O

Stepwise	NN	O	O
lineage	NN	O	O
restriction	NN	O	O
of	NN	O	O
progenitors	NN	O	B-cell_type
in	NN	O	O
lympho-myelopoiesis	NN	O	O
.	NN	O	O

By	NN	O	O
extending	NN	O	O
the	NN	O	O
area	NN	O	O
of	NN	O	O
investigation	NN	O	O
to	NN	O	O
include	NN	O	O
the	NN	O	O
erythroid	NN	O	B-cell_type
lineage	NN	O	I-cell_type
,	NN	O	O
more	NN	O	O
convincing	NN	O	O
evidence	NN	O	O
for	NN	O	O
the	NN	O	O
ordered	NN	O	O
process	NN	O	O
was	NN	O	O
obtained	NN	O	O
.	NN	O	O

EBV	NN	O	O
utilizes	NN	O	O
CD21/CR2	NN	O	B-protein
as	NN	O	O
its	NN	O	O
receptor	NN	O	O
on	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
to	NN	O	O
initiate	NN	O	O
the	NN	O	O
infection	NN	O	O
process	NN	O	O
.	NN	O	O

We	NN	O	O
had	NN	O	O
previously	NN	O	O
shown	NN	O	O
that	NN	O	O
EBV	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
modulating	NN	O	O
the	NN	O	O
synthesis	NN	O	O
of	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
cytokines	NN	O	B-protein
.	NN	O	O

Although	NN	O	O
there	NN	O	O
were	NN	O	O
similarities	NN	O	O
among	NN	O	O
the	NN	O	O
mutational	NN	O	O
patterns	NN	O	O
derived	NN	O	O
from	NN	O	O
N-OH-AAF-treated	NN	O	O
rats	NN	O	O
(	NN	O	O
e.g.	NN	O	O
,	NN	O	O
G	NN	O	O
:	NN	O	O
C	NN	O	O
--	NN	O	O
>	NN	O	O
T	NN	O	O
:	NN	O	O
A	NN	O	O
transversion	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
mutation	NN	O	O
in	NN	O	O
all	NN	O	O
mutation	NN	O	O
sets	NN	O	O
)	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
patterns	NN	O	O
of	NN	O	O
basepair	NN	O	O
substitution	NN	O	O
and	NN	O	O
frameshift	NN	O	O
mutation	NN	O	O
between	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
spleen	NN	O	B-cell_type
lymphocyte	NN	O	I-cell_type
lacI	NN	O	I-cell_type
mutants	NN	O	I-cell_type
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
and	NN	O	O
between	NN	O	O
the	NN	O	O
spleen	NN	O	B-cell_type
lymphocyte	NN	O	I-cell_type
lacI	NN	O	B-cell_type
and	NN	O	I-cell_type
hprt	NN	O	I-cell_type
mutants	NN	O	I-cell_type
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.04	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
cleavage	NN	O	O
of	NN	O	O
Gads	NN	O	B-protein
in	NN	O	O
vivo	NN	O	O
could	NN	O	O
function	NN	O	O
to	NN	O	O
alter	NN	O	O
signalling	NN	O	O
downstream	NN	O	O
of	NN	O	O
the	NN	O	O
T	NN	O	B-protein
cell	NN	O	I-protein
receptor	NN	O	I-protein
by	NN	O	O
disrupting	NN	O	O
cross	NN	O	O
talk	NN	O	O
between	NN	O	O
SLP-76	NN	O	B-protein
and	NN	O	O
LAT	NN	O	B-protein
.	NN	O	O

EAE	NN	O	O
was	NN	O	O
actively	NN	O	O
induced	NN	O	O
in	NN	O	O
C57BL/6	NN	O	O
mice	NN	O	O
using	NN	O	O
an	NN	O	O
encephalitogenic	NN	O	O
myelin	NN	O	B-protein
oligodendrocyte	NN	O	I-protein
glycoprotein	NN	O	I-protein
(	NN	O	O
MOG	NN	O	B-protein
(	NN	O	I-protein
35-55	NN	O	I-protein
)	NN	O	I-protein
)	NN	O	O
peptide	NN	O	O
.	NN	O	O

Core-binding	NN	O	B-protein
factor	NN	O	I-protein
beta	NN	O	I-protein
(	NN	O	O
CBFbeta	NN	O	B-protein
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
CBFbeta-smooth	NN	O	B-protein
muscle	NN	O	I-protein
myosin	NN	O	I-protein
heavy	NN	O	I-protein
chain	NN	O	I-protein
,	NN	O	O
rescues	NN	O	O
definitive	NN	O	O
hematopoiesis	NN	O	O
in	NN	O	O
CBFbeta	NN	O	B-protein
-deficient	NN	O	O
embryonic	NN	O	B-cell_type
stem	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Synthetic	NN	O	O
high	NN	O	O
affinity	NN	O	O
peroxisome	NN	O	O
proliferator-activated	NN	O	O
receptor	NN	O	O
(	NN	O	O
PPAR	NN	O	O
)	NN	O	O
agonists	NN	O	O
are	NN	O	O
known	NN	O	O
,	NN	O	O
but	NN	O	O
biologic	NN	O	O
ligands	NN	O	O
are	NN	O	O
of	NN	O	O
low	NN	O	O
affinity	NN	O	O
.	NN	O	O

Influenza	NN	O	O
A	NN	O	O
virus-induced	NN	O	O
IFN-alpha/beta	NN	O	B-protein
is	NN	O	O
essential	NN	O	O
in	NN	O	O
host	NN	O	O
's	NN	O	O
antiviral	NN	O	O
defence	NN	O	O
by	NN	O	O
activating	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
antiviral	NN	O	B-DNA
Mx	NN	O	I-DNA
,	NN	O	O
PKR	NN	O	B-DNA
and	NN	O	I-DNA
oligoadenylate	NN	O	I-DNA
synthetase	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
hprt	NN	O	O
and	NN	O	O
lacI	NN	O	O
mutant	NN	O	O
frequency	NN	O	O
with	NN	O	O
DNA	NN	O	O
adduct	NN	O	O
formation	NN	O	O
in	NN	O	O
N-hydroxy-2-acetylaminofluorene-treated	NN	O	O
Big	NN	O	O
Blue	NN	O	O
rats	NN	O	O
.	NN	O	O

Also	NN	O	O
at	NN	O	O
6	NN	O	O
weeks	NN	O	O
,	NN	O	O
rats	NN	O	O
given	NN	O	O
one	NN	O	O
,	NN	O	O
two	NN	O	O
,	NN	O	O
or	NN	O	O
four	NN	O	O
doses	NN	O	O
of	NN	O	O
N-OH-AAF	NN	O	O
had	NN	O	O
lacI	NN	O	O
mutant	NN	O	O
frequencies	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
of	NN	O	O
97.6	NN	O	O
,	NN	O	O
155.6	NN	O	O
,	NN	O	O
and	NN	O	O
406.8	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-6	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
control	NN	O	O
frequency	NN	O	O
of	NN	O	O
25.7	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-6	NN	O	O
)	NN	O	O
;	NN	O	O
rats	NN	O	O
given	NN	O	O
four	NN	O	O
doses	NN	O	O
had	NN	O	O
lacI	NN	O	O
mutant	NN	O	O
frequencies	NN	O	O
in	NN	O	O
spleen	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
of	NN	O	O
55.8	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-6	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
control	NN	O	O
frequency	NN	O	O
of	NN	O	O
20.4	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-6	NN	O	O
)	NN	O	O
.	NN	O	O

Intense	NN	O	O
interest	NN	O	O
is	NN	O	O
focused	NN	O	O
on	NN	O	O
PPAR-gamma	NN	O	B-protein
and	NN	O	O
its	NN	O	O
ligands	NN	O	O
owing	NN	O	O
to	NN	O	O
its	NN	O	O
putative	NN	O	O
role	NN	O	O
in	NN	O	O
adipocyte	NN	O	O
differentiation	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
NF-kappaB	NN	O	O
inhibition	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
can	NN	O	O
alter	NN	O	O
lung	NN	O	O
inflammation	NN	O	O
induced	NN	O	O
by	NN	O	O
systemic	NN	O	O
LPS	NN	O	O
treatment	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
liver-lung	NN	O	O
interaction	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
inflammatory	NN	O	O
response	NN	O	O
of	NN	O	O
the	NN	O	O
lung	NN	O	O
.	NN	O	O

We	NN	O	O
demonstrate	NN	O	O
in	NN	O	O
this	NN	O	O
report	NN	O	O
that	NN	O	O
retroviral	NN	O	O
expression	NN	O	O
of	NN	O	O
activated	NN	O	O
Notch1	NN	O	B-protein
in	NN	O	O
mouse	NN	O	B-cell_type
thymocytes	NN	O	I-cell_type
abrogates	NN	O	O
differentiation	NN	O	O
of	NN	O	O
immature	NN	O	B-cell_type
CD4+CD8+	NN	O	I-cell_type
thymocytes	NN	O	I-cell_type
into	NN	O	O
both	NN	O	O
CD4	NN	O	B-cell_type
and	NN	O	I-cell_type
CD8	NN	O	I-cell_type
mature	NN	O	I-cell_type
single-positive	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
Runx2	NN	O	B-DNA
(	NN	O	O
Cbfa1	NN	O	B-DNA
,	NN	O	O
Pebp2alphaA	NN	O	B-DNA
,	NN	O	O
Aml3	NN	O	B-DNA
)	NN	O	O
gene	NN	O	O
was	NN	O	O
previously	NN	O	O
identified	NN	O	O
as	NN	O	O
a	NN	O	O
frequent	NN	O	O
target	NN	O	O
for	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
by	NN	O	O
proviral	NN	O	O
insertion	NN	O	O
in	NN	O	O
T-cell	NN	O	O
lymphomas	NN	O	O
of	NN	O	O
CD2-MYC	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
.	NN	O	O

Neonatal	NN	O	O
infection	NN	O	O
of	NN	O	O
CD2-Runx2	NN	O	O
mice	NN	O	O
with	NN	O	O
Moloney	NN	O	O
murine	NN	O	O
leukaemia	NN	O	O
virus	NN	O	O
(	NN	O	O
Moloney	NN	O	O
MLV	NN	O	O
)	NN	O	O
also	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
dramatic	NN	O	O
acceleration	NN	O	O
of	NN	O	O
tumour	NN	O	O
onset	NN	O	O
.	NN	O	O

TRAIL	NN	O	O
expression	NN	O	O
on	NN	O	O
immature	NN	O	B-cell_type
CD34DCs	NN	O	I-cell_type
or	NN	O	O
MoDCs	NN	O	B-cell_type
was	NN	O	O
greatly	NN	O	O
up-regulated	NN	O	O
after	NN	O	O
IFN-beta	NN	O	B-protein
stimulation	NN	O	O
.	NN	O	O

-DOCSTART-	O

CD56	NN	O	B-cell_type
(	NN	O	I-cell_type
+bright	NN	O	I-cell_type
)	NN	O	I-cell_type
,	NN	O	O
but	NN	O	O
not	NN	O	O
CD56	NN	O	B-cell_type
(	NN	O	I-cell_type
+dim	NN	O	I-cell_type
)	NN	O	I-cell_type
,	NN	O	O
NK	NN	O	B-cell_type
cells	NN	O	I-cell_type
constitutively	NN	O	O
express	NN	O	O
TCF-1	NN	O	B-protein
by	NN	O	O
reverse	NN	O	O
transcriptase	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
and	NN	O	O
Western	NN	O	O
blot	NN	O	O
analysis	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
TCF-1	NN	O	B-protein
does	NN	O	O
not	NN	O	O
target	NN	O	O
human	NN	O	B-DNA
killer	NN	O	I-DNA
immunoglobulin	NN	O	I-DNA
receptor	NN	O	I-DNA
genes	NN	O	I-DNA
,	NN	O	O
TCF-1	NN	O	B-protein
is	NN	O	O
uniquely	NN	O	O
expressed	NN	O	O
in	NN	O	O
circulating	NN	O	O
CD56	NN	O	B-cell_type
(	NN	O	I-cell_type
+bright	NN	O	I-cell_type
)	NN	O	I-cell_type
NK	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
specific	NN	O	O
TCF-1	NN	O	B-protein
isoforms	NN	O	I-protein
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
regulating	NN	O	O
NK	NN	O	O
differentiation	NN	O	O
from	NN	O	O
a	NN	O	O
common	NN	O	O
NK/T-cell	NN	O	B-cell_type
progenitor	NN	O	I-cell_type
.	NN	O	O

While	NN	O	O
in	NN	O	O
most	NN	O	O
tissues	NN	O	O
all	NN	O	O
Gadd45	NN	O	B-DNA
family	NN	O	I-DNA
members	NN	O	I-DNA
are	NN	O	O
expressed	NN	O	O
,	NN	O	O
Gadd45gamma	NN	O	B-DNA
is	NN	O	O
the	NN	O	O
only	NN	O	O
member	NN	O	O
that	NN	O	O
is	NN	O	O
induced	NN	O	O
by	NN	O	O
IL-2	NN	O	B-protein
.	NN	O	O

A	NN	O	O
marked	NN	O	O
accumulation	NN	O	O
of	NN	O	O
CD68-positive	NN	O	B-cell_type
cells	NN	O	I-cell_type
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
upper	NN	O	O
dermis	NN	O	O
.	NN	O	O

The	NN	O	O
basic	NN	O	B-protein
helix-loop-helix	NN	O	I-protein
(	NN	O	I-protein
bHLH	NN	O	I-protein
)	NN	O	I-protein
proteins	NN	O	I-protein
E12	NN	O	B-protein
and	NN	O	O
E47	NN	O	B-protein
and	NN	O	O
an	NN	O	O
inhibitor	NN	O	B-protein
HLH	NN	O	I-protein
protein	NN	O	I-protein
,	NN	O	O
Id3	NN	O	B-protein
,	NN	O	O
play	NN	O	O
key	NN	O	O
roles	NN	O	O
in	NN	O	O
thymocyte	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Terminally	NN	O	B-cell_type
differentiated	NN	O	I-cell_type
skin	NN	O	I-cell_type
mast	NN	O	I-cell_type
cells	NN	O	I-cell_type
also	NN	O	O
failed	NN	O	O
to	NN	O	O
up-modulate	NN	O	O
their	NN	O	O
ICAM-3	NN	O	B-protein
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
requirement	NN	O	O
for	NN	O	O
some	NN	O	O
degree	NN	O	O
of	NN	O	O
immaturity	NN	O	O
for	NN	O	O
the	NN	O	O
process	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
review	NN	O	O
,	NN	O	O
we	NN	O	O
re-examine	NN	O	O
the	NN	O	O
concept	NN	O	O
of	NN	O	O
co-stimulation	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
self-reactive	NN	O	B-cell_type
CD8	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
Des	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
transiently	NN	O	O
activated	NN	O	O
,	NN	O	O
then	NN	O	O
became	NN	O	O
unresponsive	NN	O	O
and	NN	O	O
were	NN	O	O
further	NN	O	O
deleted	NN	O	O
.	NN	O	O

Lymphocytes	NN	O	B-cell_type
have	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
investigate	NN	O	O
many	NN	O	O
cellular	NN	O	O
processes	NN	O	O
,	NN	O	O
including	NN	O	O
lineage	NN	O	O
commitment	NN	O	O
,	NN	O	O
differentiation	NN	O	O
,	NN	O	O
proliferation	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

By	NN	O	O
using	NN	O	O
these	NN	O	O
compounds	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
whether	NN	O	O
distinct	NN	O	O
RAR	NN	O	B-protein
-dependent	NN	O	O
and	NN	O	O
RXR	NN	O	B-protein
-dependent	NN	O	O
pathways	NN	O	O
operate	NN	O	O
to	NN	O	O
mediate	NN	O	O
the	NN	O	O
diverse	NN	O	O
activities	NN	O	O
of	NN	O	O
retinoids	NN	O	O
,	NN	O	O
particularly	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
RXR	NN	O	B-protein
pathway	NN	O	O
on	NN	O	O
cellular	NN	O	O
function	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
that	NN	O	O
the	NN	O	O
bulk	NN	O	O
PTP	NN	O	B-protein
activity	NN	O	O
associated	NN	O	O
with	NN	O	O
T	NN	O	B-cell_type
cell	NN	O	I-cell_type
membrane	NN	O	O
is	NN	O	O
present	NN	O	O
outside	NN	O	O
the	NN	O	O
lipid	NN	O	O
rafts	NN	O	O
,	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
sucrose	NN	O	O
density	NN	O	O
gradient	NN	O	O
sedimentation	NN	O	O
.	NN	O	O

Monocyte	NN	O	B-protein
chemoattractant	NN	O	I-protein
protein-1	NN	O	I-protein
(	NN	O	O
MCP-1	NN	O	B-protein
)	NN	O	O
is	NN	O	O
a	NN	O	O
potent	NN	O	O
chemokine	NN	O	B-protein
that	NN	O	O
stimulates	NN	O	O
the	NN	O	O
migration	NN	O	O
of	NN	O	O
monocytes	NN	O	B-cell_type
into	NN	O	O
the	NN	O	O
intima	NN	O	O
of	NN	O	O
the	NN	O	O
arterial	NN	O	O
wall	NN	O	O
.	NN	O	O

Further	NN	O	O
,	NN	O	O
surface	NN	O	O
immunoglobulin	NN	O	O
signaling	NN	O	O
for	NN	O	O
inducible	NN	O	O
Fas	NN	O	B-protein
-resistance	NN	O	O
bypasses	NN	O	O
Btk	NN	O	B-protein
,	NN	O	O
requires	NN	O	O
NF-kappaB	NN	O	B-protein
,	NN	O	O
and	NN	O	O
entails	NN	O	O
new	NN	O	O
macromolecular	NN	O	O
synthesis	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
NFATc1	NN	O	B-protein
and	NN	O	O
NFATc2	NN	O	B-protein
are	NN	O	O
dispensable	NN	O	O
for	NN	O	O
inflammatory	NN	O	O
reactivity	NN	O	O
but	NN	O	O
are	NN	O	O
required	NN	O	O
for	NN	O	O
effector	NN	O	O
differentiation	NN	O	O
,	NN	O	O
while	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
NFATs	NN	O	B-protein
regulate	NN	O	O
both	NN	O	O
normal	NN	O	O
homeostasis	NN	O	O
and	NN	O	O
differentiation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Seven	NN	O	O
nondiabetic	NN	O	O
obese	NN	O	O
patients	NN	O	O
were	NN	O	O
given	NN	O	O
400	NN	O	O
mg	NN	O	O
troglitazone	NN	O	O
daily	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

Plasma	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
insulin	NN	O	O
glucose	NN	O	O
,	NN	O	O
TNFalpha	NN	O	B-protein
,	NN	O	O
sICAM	NN	O	B-protein
,	NN	O	O
MCP-1	NN	O	B-protein
,	NN	O	O
PAI-1	NN	O	B-protein
,	NN	O	O
CRP	NN	O	B-protein
,	NN	O	O
and	NN	O	O
IL-10	NN	O	B-protein
.	NN	O	O

Plasma	NN	O	O
glucose	NN	O	O
concentrations	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
significantly	NN	O	O
.	NN	O	O

ATRA	NN	O	O
and	NN	O	O
its	NN	O	O
metabolites	NN	O	O
could	NN	O	O
induce	NN	O	O
NB4	NN	O	B-cell_line
cells	NN	O	I-cell_line
differentiation	NN	O	O
with	NN	O	O
similar	NN	O	O
activity	NN	O	O
,	NN	O	O
as	NN	O	O
evaluated	NN	O	O
by	NN	O	O
cell	NN	O	O
morphology	NN	O	O
,	NN	O	O
by	NN	O	O
the	NN	O	O
nitroblue	NN	O	O
tetrazolium	NN	O	O
reduction	NN	O	O
test	NN	O	O
(	NN	O	O
82-88	NN	O	O
%	NN	O	O
at	NN	O	O
120	NN	O	O
h	NN	O	O
)	NN	O	O
or	NN	O	O
by	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
maturation	NN	O	B-protein
specific	NN	O	I-protein
cell	NN	O	I-protein
surface	NN	O	I-protein
marker	NN	O	I-protein
CD11c	NN	O	I-protein
.	NN	O	O

The	NN	O	O
ATRA	NN	O	O
metabolites	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
exert	NN	O	O
their	NN	O	O
differentiation	NN	O	O
effects	NN	O	O
via	NN	O	O
the	NN	O	O
RAR	NN	O	B-protein
alpha	NN	O	I-protein
nuclear	NN	O	I-protein
receptors	NN	O	I-protein
,	NN	O	O
because	NN	O	O
the	NN	O	O
RAR	NN	O	O
alpha-specific	NN	O	O
antagonist	NN	O	O
BMS614	NN	O	O
blocked	NN	O	O
metabolite-induced	NN	O	O
CD11c	NN	O	O
expression	NN	O	O
in	NN	O	O
NB4	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Expression	NN	O	O
of	NN	O	O
oestrogen	NN	O	B-protein
receptors	NN	O	I-protein
(	NN	O	O
ER	NN	O	B-protein
)	NN	O	O
and	NN	O	O
progesterone	NN	O	B-protein
receptors	NN	O	I-protein
(	NN	O	O
PR	NN	O	B-protein
)	NN	O	O
was	NN	O	O
examined	NN	O	O
using	NN	O	O
immunohistochemistry	NN	O	O
in	NN	O	O
formalin	NN	O	O
fixed	NN	O	O
nasal	NN	O	O
polyp	NN	O	O
tissues	NN	O	O
from	NN	O	O
47	NN	O	O
subjects	NN	O	O
.	NN	O	O

-DOCSTART-	O

Lymphokine	NN	O	B-protein
dependence	NN	O	O
of	NN	O	O
STAT3	NN	O	O
activation	NN	O	O
produced	NN	O	O
by	NN	O	O
surface	NN	O	O
immunoglobulin	NN	O	O
cross-linking	NN	O	O
and	NN	O	O
by	NN	O	O
phorbol	NN	O	O
ester	NN	O	O
plus	NN	O	O
calcium	NN	O	O
ionophore	NN	O	O
treatment	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

sIg	NN	O	B-protein
-induced	NN	O	O
STAT3	NN	O	O
activation	NN	O	O
was	NN	O	O
completely	NN	O	O
inhibited	NN	O	O
by	NN	O	O
combining	NN	O	O
IL-6-	NN	O	B-protein
and	NN	O	I-protein
IL-10-specific	NN	O	I-protein
neutralizing	NN	O	I-protein
antibodies	NN	O	I-protein
,	NN	O	O
or	NN	O	O
by	NN	O	O
adding	NN	O	O
individual	NN	O	O
neutralizing	NN	O	B-protein
antibodies	NN	O	I-protein
to	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
obtained	NN	O	O
from	NN	O	O
lymphokine-deficient	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
octamer	NN	O	B-DNA
element	NN	O	I-DNA
is	NN	O	O
common	NN	O	O
to	NN	O	O
all	NN	O	O
Ig	NN	O	B-DNA
promoters	NN	O	I-DNA
and	NN	O	O
pivotal	NN	O	O
for	NN	O	O
their	NN	O	O
function	NN	O	O
.	NN	O	O

We	NN	O	O
now	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
a	NN	O	O
16	NN	O	O
amino	NN	O	O
acid	NN	O	O
peptide	NN	O	O
from	NN	O	O
antennapedia	NN	O	O
can	NN	O	O
facilitate	NN	O	O
the	NN	O	O
cytoplasmic	NN	O	O
uptake	NN	O	O
of	NN	O	O
CTL	NN	O	O
epitope	NN	O	O
9-mer	NN	O	O
peptides	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
obtained	NN	O	O
PBL	NN	O	B-cell_type
from	NN	O	O
Epstein-Barr	NN	O	O
virus	NN	O	O
(	NN	O	O
EBV	NN	O	O
)	NN	O	O
IgG	NN	O	B-protein
antibody	NN	O	I-protein
positive	NN	O	O
kidney	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
(	NN	O	O
R	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
living-related	NN	O	O
donors	NN	O	O
(	NN	O	O
LRD	NN	O	O
)	NN	O	O
one	NN	O	O
year	NN	O	O
after	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

EBV-specific	NN	O	B-cell_type
CTL	NN	O	I-cell_type
were	NN	O	O
then	NN	O	O
generated	NN	O	O
in	NN	O	O
vitro	NN	O	O
by	NN	O	O
stimulating	NN	O	O
PBL	NN	O	B-cell_type
with	NN	O	O
autologous	NN	O	O
EBV-transformed	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
EBV-B	NN	O	B-cell_type
)	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
autologous	NN	O	B-cell_type
BMC	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
addition	NN	O	O
of	NN	O	O
BMC	NN	O	B-cell_type
to	NN	O	O
the	NN	O	O
EBV-CTL	NN	O	B-cell_type
generation	NN	O	I-cell_type
cultures	NN	O	I-cell_type
increased	NN	O	O
the	NN	O	O
intracellular	NN	O	O
expression	NN	O	O
in	NN	O	O
CD3+	NN	O	B-cell_type
cells	NN	O	I-cell_type
of	NN	O	O
IL-4	NN	O	B-protein
,	NN	O	I-protein
-5	NN	O	I-protein
,	NN	O	I-protein
-6	NN	O	I-protein
,	NN	O	I-protein
-10	NN	O	I-protein
,	NN	O	I-protein
and	NN	O	I-protein
-13	NN	O	I-protein
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
of	NN	O	O
Pax-5a	NN	O	B-protein
but	NN	O	O
not	NN	O	O
Pax-5d	NN	O	B-protein
protein	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
aged	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
while	NN	O	O
Western	NN	O	O
blot	NN	O	O
analyses	NN	O	O
showed	NN	O	O
that	NN	O	O
similar	NN	O	O
levels	NN	O	O
of	NN	O	O
Pax-5a	NN	O	B-protein
and	NN	O	I-protein
5d	NN	O	I-protein
proteins	NN	O	O
were	NN	O	O
present	NN	O	O
in	NN	O	O
both	NN	O	O
age	NN	O	O
groups	NN	O	O
.	NN	O	O

-DOCSTART-	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
NF-kappaB/Rel/IkappaBalpha	NN	O	O
system	NN	O	O
can	NN	O	O
regulate	NN	O	O
cytokine	NN	O	B-protein
receptor	NN	O	I-protein
capacitation	NN	O	O
through	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
downstream	NN	O	O
signaling	NN	O	O
by	NN	O	O
the	NN	O	O
Stat	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
family	NN	O	I-protein
.	NN	O	O

BMS-189453	NN	O	O
was	NN	O	O
then	NN	O	O
administered	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
2	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
or	NN	O	O
50	NN	O	O
mg/kg	NN	O	O
to	NN	O	O
male	NN	O	O
rats	NN	O	O
for	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
or	NN	O	O
7	NN	O	O
consecutive	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
Egr2	NN	O	B-protein
and	NN	O	O
Egr3	NN	O	B-protein
are	NN	O	O
potent	NN	O	O
activators	NN	O	O
of	NN	O	O
FasL	NN	O	O
expression	NN	O	O
.	NN	O	O

-DOCSTART-	O

Marrow	NN	O	O
stromal	NN	O	O
support	NN	O	O
of	NN	O	O
granulopoiesis	NN	O	O
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
plating	NN	O	O
CD34	NN	O	B-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
cells	NN	O	I-cell_type
on	NN	O	O
preformed	NN	O	O
stromal	NN	O	O
layers	NN	O	O
.	NN	O	O

Proliferation	NN	O	O
of	NN	O	O
32D	NN	O	B-cell_line
cells	NN	O	I-cell_line
expressing	NN	O	O
the	NN	O	O
mutated	NN	O	B-protein
receptor	NN	O	I-protein
and	NN	O	O
STAT5	NN	O	O
activation	NN	O	O
were	NN	O	O
improved	NN	O	O
by	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
G-CSF	NN	O	B-protein
and	NN	O	O
dexamethasone	NN	O	O
.	NN	O	O

When	NN	O	O
small	NN	O	O
daily	NN	O	O
doses	NN	O	O
of	NN	O	O
oral	NN	O	O
prednisone	NN	O	O
were	NN	O	O
then	NN	O	O
administered	NN	O	O
to	NN	O	O
the	NN	O	O
patient	NN	O	O
with	NN	O	O
conventional	NN	O	O
doses	NN	O	O
of	NN	O	O
subcutaneous	NN	O	B-protein
G-CSF	NN	O	I-protein
,	NN	O	O
the	NN	O	O
patient	NN	O	O
responded	NN	O	O
with	NN	O	O
increased	NN	O	O
neutrophil	NN	O	O
numbers	NN	O	O
and	NN	O	O
with	NN	O	O
a	NN	O	O
complete	NN	O	O
reversal	NN	O	O
of	NN	O	O
the	NN	O	O
infectious	NN	O	O
problems	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
9-cRA	NN	O	O
diminished	NN	O	O
monocyte	NN	O	O
adhesion	NN	O	O
to	NN	O	O
FCS-stimulated	NN	O	B-cell_line
CHMC	NN	O	I-cell_line
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
mammalian	NN	O	B-DNA
defensin	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
region	NN	O	I-DNA
contains	NN	O	O
novel	NN	O	O
distal	NN	O	B-DNA
regulatory	NN	O	I-DNA
elements	NN	O	I-DNA
that	NN	O	O
can	NN	O	O
be	NN	O	O
addressed	NN	O	O
by	NN	O	O
the	NN	O	O
AHR	NN	O	B-protein
to	NN	O	O
induce	NN	O	O
IL-2	NN	O	B-DNA
and	NN	O	O
can	NN	O	O
cooperate	NN	O	O
with	NN	O	O
the	NN	O	O
proximal	NN	O	B-DNA
promoter	NN	O	I-DNA

In	NN	O	O
comparison	NN	O	O
,	NN	O	O
these	NN	O	O
changes	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
mutant	NN	O	O
mice	NN	O	O
with	NN	O	O
UUO	NN	O	O
.	NN	O	O

HLA-DQ	NN	O	B-protein
tetramers	NN	O	I-protein
identify	NN	O	O
epitope-specific	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
of	NN	O	O
herpes	NN	O	O
simplex	NN	O	O
virus	NN	O	O
type	NN	O	O
2-infected	NN	O	O
individuals	NN	O	O
:	NN	O	O
direct	NN	O	O
detection	NN	O	O
of	NN	O	O
immunodominant	NN	O	B-cell_type
antigen-responsive	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
reintroduction	NN	O	O
of	NN	O	O
BOB.1/OBF.1	NN	O	B-protein
and	NN	O	O
Oct2	NN	O	B-protein
into	NN	O	O
cultured	NN	O	O
HRS	NN	O	B-cell_type
cells	NN	O	I-cell_type
restored	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
cotransduced	NN	O	O
immunoglobulin	NN	O	B-DNA
promoter	NN	O	I-DNA
constructs	NN	O	I-DNA
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
dismiss	NN	O	O
the	NN	O	O
concept	NN	O	O
that	NN	O	O
the	NN	O	O
different	NN	O	O
immunoglobulin	NN	O	O
expression	NN	O	O
in	NN	O	O
cHD	NN	O	O
and	NN	O	O
LPHD	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
disrupting	NN	O	O
mutations	NN	O	O
of	NN	O	O
immunoglobulin	NN	O	B-DNA
V	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
cHD	NN	O	O
but	NN	O	O
is	NN	O	O
most	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
down-regulation	NN	O	O
of	NN	O	O
Oct2	NN	O	B-protein
and/or	NN	O	O
BOB.1/OBF.1	NN	O	B-protein
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
untreated	NN	O	O
control	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
a	NN	O	O
marked	NN	O	O
increase	NN	O	O
in	NN	O	O
apoptosis	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
NF-kappa	NN	O	O
B	NN	O	O
DNA-binding	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
marked	NN	O	O
decrease	NN	O	O
in	NN	O	O
nuclear	NN	O	O
p65	NN	O	O
(	NN	O	O
Rel	NN	O	O
A	NN	O	O
)	NN	O	O
expression	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
cells	NN	O	O
from	NN	O	O
both	NN	O	O
CTCL	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
after	NN	O	O
chemical	NN	O	O
NF-kappa	NN	O	O
B	NN	O	O
inhibition	NN	O	O
.	NN	O	O

Strict	NN	O	O
control	NN	O	O
of	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
replication	NN	O	O
by	NN	O	O
a	NN	O	O
genetic	NN	O	O
switch	NN	O	O
:	NN	O	O
Tet	NN	O	O
for	NN	O	O
Tat	NN	O	O
.	NN	O	O

The	NN	O	O
research	NN	O	O
described	NN	O	O
herein	NN	O	O
evaluates	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
functional	NN	O	O
significance	NN	O	O
of	NN	O	O
peroxisome	NN	O	B-protein
proliferator	NN	O	I-protein
activator	NN	O	I-protein
receptor-gamma	NN	O	I-protein
(	NN	O	I-protein
PPAR-gamma	NN	O	I-protein
)	NN	O	I-protein
on	NN	O	O
B-lineage	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
STAT3	NN	O	B-protein
activation	NN	O	O
contributed	NN	O	O
to	NN	O	O
accumulation	NN	O	O
of	NN	O	O
the	NN	O	O
leukemic	NN	O	B-cell_type
LGL	NN	O	I-cell_type
clones	NN	O	I-cell_type
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
investigation	NN	O	O
should	NN	O	O
focus	NN	O	O
on	NN	O	O
novel	NN	O	O
strategies	NN	O	O
targeting	NN	O	O
STAT3	NN	O	B-protein
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
LGL	NN	O	O
leukemia	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Eosinophils	NN	O	B-cell_type
are	NN	O	O
now	NN	O	O
known	NN	O	O
to	NN	O	O
produce	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
proinflammatory	NN	O	B-protein
cytokines	NN	O	I-protein
,	NN	O	O
although	NN	O	O
the	NN	O	O
molecular	NN	O	O
factors	NN	O	O
that	NN	O	O
regulate	NN	O	O
their	NN	O	O
production	NN	O	O
are	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
BLyS	NN	O	B-protein
binding	NN	O	O
to	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
results	NN	O	O
in	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
and	NN	O	O
the	NN	O	O
Ets	NN	O	B-protein
family	NN	O	I-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
ELF-1	NN	O	B-protein
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
mRNA	NN	O	O
for	NN	O	O
Polo-like	NN	O	B-protein
kinase	NN	O	I-protein
(	NN	O	O
PLK	NN	O	B-protein
)	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
composed	NN	O	O
of	NN	O	O
a	NN	O	O
fusion	NN	O	O
between	NN	O	O
full-length	NN	O	B-protein
Nef	NN	O	I-protein
and	NN	O	O
the	NN	O	O
estrogen	NN	O	B-protein
receptor	NN	O	I-protein
hormone-binding	NN	O	I-protein
domain	NN	O	I-protein
(	NN	O	O
Nef-ER	NN	O	B-protein
)	NN	O	O
.	NN	O	O

The	NN	O	O
facts	NN	O	O
that	NN	O	O
PMN	NN	O	B-cell_type
influx	NN	O	O
was	NN	O	O
preceded	NN	O	O
by	NN	O	O
increased	NN	O	O
MIP-2	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
MIP-2	NN	O	B-protein
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
NaVO3-induced	NN	O	O
pulmonary	NN	O	O
inflammation	NN	O	O
,	NN	O	O
whereas	NN	O	O
increased	NN	O	O
MIP-1alpha	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
decreased	NN	O	O
AMs	NN	O	B-cell_type
in	NN	O	O
BAL	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
suggesting	NN	O	O
AMs	NN	O	B-cell_type
might	NN	O	O
be	NN	O	O
activated	NN	O	O
by	NN	O	O
MIP-1alpha	NN	O	B-protein
,	NN	O	O
adherent	NN	O	O
to	NN	O	O
the	NN	O	O
lining	NN	O	O
surface	NN	O	O
of	NN	O	O
the	NN	O	O
airways	NN	O	O
and	NN	O	O
then	NN	O	O
resistant	NN	O	O
to	NN	O	O
be	NN	O	O
washed	NN	O	O
out	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
our	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
MIP-2	NN	O	B-protein
is	NN	O	O
an	NN	O	O
important	NN	O	O
mediator	NN	O	O
of	NN	O	O
NaVO3-induced	NN	O	O
pulmonary	NN	O	O
inflammation	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
model	NN	O	O
.	NN	O	O

IKKs	NN	O	B-protein
recruited	NN	O	O
to	NN	O	O
these	NN	O	O
lipid	NN	O	O
rafts	NN	O	O
were	NN	O	O
capable	NN	O	O
of	NN	O	O
phosphorylating	NN	O	O
a	NN	O	O
recombinant	NN	O	O
IkappaBalpha	NN	O	O
sustrate	NN	O	O
.	NN	O	O

(	NN	O	O
Blood.	NN	O	O
2000	NN	O	O
;	NN	O	O
96	NN	O	O
:	NN	O	O
4142-4151	NN	O	O
)	NN	O	O

The	NN	O	O
two	NN	O	O
latter	NN	O	O
phenomena	NN	O	O
were	NN	O	O
reproduced	NN	O	O
by	NN	O	O
the	NN	O	O
cross-linking	NN	O	O
of	NN	O	O
the	NN	O	O
alpha3	NN	O	B-protein
,	NN	O	O
alpha6	NN	O	B-protein
,	NN	O	O
beta1	NN	O	B-protein
and	NN	O	I-protein
beta4	NN	O	I-protein
integrins	NN	O	I-protein
,	NN	O	O
thus	NN	O	O
implying	NN	O	O
that	NN	O	O
the	NN	O	O
alpha3beta1	NN	O	B-protein
and	NN	O	I-protein
alpha6beta4	NN	O	I-protein
heterodimers	NN	O	I-protein
can	NN	O	O
signal	NN	O	O
during	NN	O	O
thymocyte	NN	O	O
adhesion	NN	O	O
.	NN	O	O

-DOCSTART-	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
cAMP-induced	NN	O	O
effects	NN	O	O
in	NN	O	O
Th2	NN	O	B-cell_type
cells	NN	O	I-cell_type
occur	NN	O	O
independently	NN	O	O
of	NN	O	O
the	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
A	NN	O	I-protein
pathway	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
the	NN	O	O
major	NN	O	O
mediator	NN	O	O
of	NN	O	O
cAMP-induced	NN	O	O
signaling	NN	O	O
events	NN	O	O
in	NN	O	O
most	NN	O	O
cell	NN	O	O
types	NN	O	O
.	NN	O	O

Epstein-Barr	NN	O	O
virus	NN	O	O
(	NN	O	O
EBV	NN	O	O
)	NN	O	O
-induced	NN	O	O
B-cell	NN	O	B-cell_type
growth	NN	O	O
transformation	NN	O	O
,	NN	O	O
a	NN	O	O
central	NN	O	O
feature	NN	O	O
of	NN	O	O
the	NN	O	O
virus	NN	O	O
'	NN	O	O
strategy	NN	O	O
for	NN	O	O
colonizing	NN	O	O
the	NN	O	O
human	NN	O	O
B-cell	NN	O	O
system	NN	O	O
,	NN	O	O
requires	NN	O	O
full	NN	O	O
virus	NN	O	O
latent	NN	O	O
gene	NN	O	O
expression	NN	O	O
and	NN	O	O
is	NN	O	O
initiated	NN	O	O
by	NN	O	O
transcription	NN	O	O
from	NN	O	O
the	NN	O	O
viral	NN	O	B-DNA
promoter	NN	O	I-DNA
Wp	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
reporter	NN	O	O
assays	NN	O	O
with	NN	O	O
mutant	NN	O	B-DNA
Wp	NN	O	I-DNA
constructs	NN	O	I-DNA
,	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
factor	NN	O	O
binding	NN	O	O
to	NN	O	O
any	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
sites	NN	O	O
severely	NN	O	O
impaired	NN	O	O
promoter	NN	O	O
activity	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
while	NN	O	O
the	NN	O	O
wild-type	NN	O	B-DNA
promoter	NN	O	I-DNA
could	NN	O	O
be	NN	O	O
activated	NN	O	O
in	NN	O	O
non-B	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
ectopic	NN	O	O
BSAP	NN	O	O
expression	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
Wp	NN	O	B-DNA
regulation	NN	O	O
by	NN	O	O
BSAP	NN	O	B-protein
helps	NN	O	O
to	NN	O	O
ensure	NN	O	O
the	NN	O	O
B-cell	NN	O	B-cell_type
specificity	NN	O	O
of	NN	O	O
EBV	NN	O	O
's	NN	O	O
growth-transforming	NN	O	O
function	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
the	NN	O	O
Lck	NN	O	B-protein
tyrosine	NN	O	I-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
by	NN	O	O
the	NN	O	O
Herpesvirus	NN	O	O
saimiri	NN	O	O
tip	NN	O	B-protein
protein	NN	O	I-protein
involves	NN	O	O
two	NN	O	O
binding	NN	O	O
interactions	NN	O	O
.	NN	O	O

A	NN	O	O
proline-rich	NN	O	B-protein
region	NN	O	I-protein
,	NN	O	O
residues	NN	O	O
132-141	NN	O	O
,	NN	O	O
binds	NN	O	O
to	NN	O	O
the	NN	O	O
SH3	NN	O	B-protein
domain	NN	O	I-protein
of	NN	O	O
the	NN	O	O
Lck	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

The	NN	O	O
proteasome	NN	O	B-protein
regulates	NN	O	O
receptor-mediated	NN	O	O
endocytosis	NN	O	O
of	NN	O	O
interleukin-2	NN	O	B-protein
.	NN	O	O

Distribution	NN	O	O
of	NN	O	O
the	NN	O	O
surface	NN	O	O
markers	NN	O	O
in	NN	O	O
the	NN	O	O
leukemic	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
did	NN	O	O
not	NN	O	O
relate	NN	O	O
to	NN	O	O
the	NN	O	O
GR	NN	O	B-protein
concentration	NN	O	O
.	NN	O	O

Clinical	NN	O	O
implications	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
human	NN	O	O
leukemia	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
normal	NN	O	B-protein
and	NN	O	I-protein
active	NN	O	I-protein
Fyn	NN	O	I-protein
stimulated	NN	O	O
transcription	NN	O	O
from	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
gene	NN	O	I-DNA
promoter	NN	O	I-DNA
when	NN	O	O
transfected	NN	O	O
cells	NN	O	O
were	NN	O	O
stimulated	NN	O	O
by	NN	O	O
concanavalin	NN	O	B-protein
A	NN	O	I-protein
plus	NN	O	O
12-O-tetradecanoylphorbol-13-acetate	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
a	NN	O	O
mutant	NN	O	B-protein
Fyn	NN	O	I-protein
,	NN	O	O
which	NN	O	O
has	NN	O	O
deletions	NN	O	O
within	NN	O	O
the	NN	O	O
SH2	NN	O	B-protein
region	NN	O	I-protein
and	NN	O	O
so	NN	O	O
is	NN	O	O
able	NN	O	O
to	NN	O	O
transform	NN	O	O
chicken	NN	O	B-cell_type
embryo	NN	O	I-cell_type
fibroblasts	NN	O	I-cell_type
,	NN	O	O
did	NN	O	O
not	NN	O	O
stimulate	NN	O	O
either	NN	O	O
the	NN	O	O
c-fos	NN	O	B-DNA
or	NN	O	I-DNA
IL-2	NN	O	I-DNA
promoter	NN	O	I-DNA
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
this	NN	O	O
region	NN	O	O
in	NN	O	O
T-cell	NN	O	B-cell_type
signaling	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
addition	NN	O	O
of	NN	O	O
sodium	NN	O	O
butyrate	NN	O	O
or	NN	O	O
1	NN	O	O
alpha	NN	O	O
,	NN	O	O
25-dihydroxyvitamin	NN	O	O
D3	NN	O	O
to	NN	O	O
HL-60	NN	O	B-cell_line
cells	NN	O	I-cell_line
induced	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
c-fos	NN	O	B-DNA
,	NN	O	I-DNA
c-jun	NN	O	I-DNA
,	NN	O	I-DNA
jun	NN	O	I-DNA
B	NN	O	I-DNA
and	NN	O	I-DNA
jun	NN	O	I-DNA
D	NN	O	I-DNA
proto-oncogenes	NN	O	I-DNA
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
marked	NN	O	O
correlation	NN	O	O
between	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
levels	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
sensitivity	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
that	NN	O	O
DEAE-cellulose	NN	O	O
chromatography	NN	O	O
of	NN	O	O
steroid-receptor	NN	O	B-protein
complexes	NN	O	I-protein
from	NN	O	O
CEM-C7	NN	O	B-cell_line
,	NN	O	O
a	NN	O	O
cloned	NN	O	B-cell_line
human	NN	O	I-cell_line
leukaemic	NN	O	I-cell_line
T-cell	NN	O	I-cell_line
line	NN	O	I-cell_line
sensitive	NN	O	O
to	NN	O	O
the	NN	O	O
cytolytic	NN	O	O
action	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
,	NN	O	O
and	NN	O	O
its	NN	O	O
steroid-resistant	NN	O	B-cell_line
subclone	NN	O	I-cell_line
4R4	NN	O	I-cell_line
demonstrated	NN	O	O
that	NN	O	O
steroid	NN	O	B-protein
receptors	NN	O	I-protein
of	NN	O	O
clone	NN	O	B-cell_line
4R4	NN	O	I-cell_line
can	NN	O	O
not	NN	O	O
form	NN	O	O
stable	NN	O	O
activated	NN	O	O
complexes	NN	O	O
.	NN	O	O

-DOCSTART-	O

Endometrial	NN	O	O
samples	NN	O	O
of	NN	O	O
women	NN	O	O
at	NN	O	O
various	NN	O	O
stages	NN	O	O
of	NN	O	O
gonadal	NN	O	O
activity	NN	O	O
after	NN	O	O
parturition	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
the	NN	O	O
presence	NN	O	O
and	NN	O	O
numbers	NN	O	O
of	NN	O	O
endometrial	NN	O	B-cell_type
granulocytes	NN	O	I-cell_type
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
this	NN	O	O
correlates	NN	O	O
with	NN	O	O
the	NN	O	O
suggestion	NN	O	O
that	NN	O	O
the	NN	O	O
granulocytes	NN	O	B-cell_type
constitute	NN	O	O
a	NN	O	O
receptor	NN	O	O
system	NN	O	O
for	NN	O	O
oestrogens	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
monocytes	NN	O	B-cell_type
and	NN	O	O
macrophages	NN	O	B-cell_type
.	NN	O	O

We	NN	O	O
have	NN	O	O
previously	NN	O	O
shown	NN	O	O
that	NN	O	O
a	NN	O	O
fragment	NN	O	O
containing	NN	O	O
bp	NN	O	B-DNA
-95	NN	O	I-DNA
to	NN	O	I-DNA
+27	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
mouse	NN	O	B-DNA
GM-CSF	NN	O	I-DNA
promoter	NN	O	I-DNA
can	NN	O	O
confer	NN	O	O
inducibility	NN	O	O
to	NN	O	O
reporter	NN	O	B-DNA
genes	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
human	NN	O	B-cell_line
Jurkat	NN	O	I-cell_line
T-cell	NN	O	I-cell_line
line	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
functional	NN	O	O
importance	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
binding	NN	O	O
sites	NN	O	O
only	NN	O	O
became	NN	O	O
apparent	NN	O	O
when	NN	O	O
combinations	NN	O	O
of	NN	O	O
mutations	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Deletion	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
T	NN	O	B-cell_type
cell	NN	O	I-cell_type
specificity	NN	O	O
was	NN	O	O
conferred	NN	O	O
by	NN	O	O
a	NN	O	O
49-bp	NN	O	B-DNA
fragment	NN	O	I-DNA
(	NN	O	O
bp	NN	O	B-DNA
-319	NN	O	I-DNA
to	NN	O	I-DNA
-270	NN	O	I-DNA
)	NN	O	O
that	NN	O	O
included	NN	O	O
a	NN	O	O
potential	NN	O	B-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
for	NN	O	O
AP-1	NN	O	B-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
6	NN	O	O
bp	NN	O	O
upstream	NN	O	O
of	NN	O	O
a	NN	O	O
binding	NN	O	B-DNA
site	NN	O	I-DNA
for	NN	O	I-DNA
Elf-1	NN	O	I-DNA
,	NN	O	O
a	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
Ets	NN	O	B-protein
family	NN	O	I-protein
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

We	NN	O	O
examined	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
certain	NN	O	O
cytokines	NN	O	O
,	NN	O	O
specifically	NN	O	O
IL-2	NN	O	B-protein
and	NN	O	O
IL-4	NN	O	B-protein
,	NN	O	O
could	NN	O	O
affect	NN	O	O
T	NN	O	O
cell	NN	O	O
response	NN	O	O
to	NN	O	O
glucocorticoids	NN	O	O
.	NN	O	O

A	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
dexamethasone	NN	O	O
radioligand-binding	NN	O	O
assay	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
(	NN	O	O
GR	NN	O	B-protein
)	NN	O	O
and	NN	O	O
dissociation	NN	O	O
constant	NN	O	O
(	NN	O	O
Kd	NN	O	O
)	NN	O	O
in	NN	O	O
PBMC	NN	O	B-cell_type
from	NN	O	O
normal	NN	O	O
donors	NN	O	O
and	NN	O	O
patients	NN	O	O
with	NN	O	O
SR	NN	O	O
asthma	NN	O	O
,	NN	O	O
cultured	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
and	NN	O	O
presence	NN	O	O
of	NN	O	O
these	NN	O	O
cytokines	NN	O	B-protein
.	NN	O	O

By	NN	O	O
morphologic	NN	O	O
criteria	NN	O	O
and	NN	O	O
thymidine	NN	O	O
incorporation	NN	O	O
,	NN	O	O
the	NN	O	O
fractions	NN	O	O
were	NN	O	O
separated	NN	O	O
into	NN	O	O
populations	NN	O	O
of	NN	O	O
G0	NN	O	B-cell_type
and	NN	O	I-cell_type
G1	NN	O	I-cell_type
phase	NN	O	I-cell_type
and	NN	O	I-cell_type
S	NN	O	I-cell_type
and	NN	O	I-cell_type
post-S	NN	O	I-cell_type
phase	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Breast	NN	O	O
cancer	NN	O	O
patients	NN	O	O
showed	NN	O	O
significant	NN	O	O
responses	NN	O	O
to	NN	O	O
MuMTV	NN	O	B-protein
(	NN	O	O
49	NN	O	O
%	NN	O	O
and	NN	O	O
to	NN	O	O
MCF-7	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
to	NN	O	O
MPMV	NN	O	B-protein
(	NN	O	O
29	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
above	NN	O	O
reactions	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
large	NN	O	O
proportion	NN	O	O
of	NN	O	O
breast	NN	O	O
cancer	NN	O	O
patients	NN	O	O
exhibit	NN	O	O
presensitization	NN	O	O
to	NN	O	O
antigenfs	NN	O	O
found	NN	O	O
in	NN	O	O
MuMTV	NN	O	B-protein
and	NN	O	O
MCF-7	NN	O	B-protein
,	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
cross-reactive	NN	O	O
with	NN	O	O
antigens	NN	O	O
in	NN	O	O
the	NN	O	O
primary	NN	O	O
cancer	NN	O	O
.	NN	O	O

Glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
levels	NN	O	O
and	NN	O	O
steroid	NN	O	O
induced	NN	O	O
inhibition	NN	O	O
of	NN	O	O
nucleic	NN	O	O
acid	NN	O	O
precursors	NN	O	O
have	NN	O	O
been	NN	O	O
examined	NN	O	O
in	NN	O	O
lymphocytes	NN	O	B-cell_type
from	NN	O	O
27	NN	O	O
patients	NN	O	O
at	NN	O	O
different	NN	O	O
stages	NN	O	O
of	NN	O	O
chronic	NN	O	O
lymphatic	NN	O	O
leukaemia	NN	O	O
.	NN	O	O

-DOCSTART-	O

However	NN	O	O
,	NN	O	O
when	NN	O	O
fused	NN	O	O
to	NN	O	O
the	NN	O	O
DNA	NN	O	B-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
of	NN	O	O
GAL	NN	O	B-protein
4	NN	O	O
and	NN	O	O
assayed	NN	O	O
on	NN	O	O
GAL4	NN	O	B-protein
binding	NN	O	I-protein
sites	NN	O	I-protein
,	NN	O	O
regions	NN	O	B-protein
YII	NN	O	I-protein
and	NN	O	I-protein
YIII	NN	O	I-protein
were	NN	O	O
each	NN	O	O
sufficient	NN	O	O
to	NN	O	O
confer	NN	O	O
activation	NN	O	O
in	NN	O	O
S.	NN	O	O
cerevisiae	NN	O	O
.	NN	O	O

The	NN	O	O
discordant	NN	O	O
mutants	NN	O	O
may	NN	O	O
reflect	NN	O	O
interactions	NN	O	O
with	NN	O	O
a	NN	O	O
variable	NN	O	B-protein
domain	NN	O	I-protein
of	NN	O	O
a	NN	O	O
conserved	NN	O	O
component	NN	O	O
or	NN	O	O
unique	NN	O	O
interactions	NN	O	O
with	NN	O	O
specialized	NN	O	O
components	NN	O	O
of	NN	O	O
the	NN	O	O
basal	NN	O	O
transcription	NN	O	O
apparatus	NN	O	O
in	NN	O	O
different	NN	O	O
cells	NN	O	O
.	NN	O	O

In	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
,	NN	O	O
triggering	NN	O	O
of	NN	O	O
the	NN	O	O
T	NN	O	B-protein
cell	NN	O	I-protein
receptor	NN	O	I-protein
(	NN	O	O
TCR	NN	O	B-protein
)	NN	O	O
induces	NN	O	O
several	NN	O	O
signaling	NN	O	O
cascades	NN	O	O
which	NN	O	O
ultimately	NN	O	O
synergize	NN	O	O
to	NN	O	O
induce	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	O
activated	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
NFAT	NN	O	B-cell_line
)	NN	O	O
,	NN	O	O
a	NN	O	O
DNA	NN	O	B-protein
binding	NN	O	I-protein
complex	NN	O	I-protein
critical	NN	O	O
to	NN	O	O
the	NN	O	O
inducibility	NN	O	O
and	NN	O	O
T	NN	O	O
cell	NN	O	O
specificity	NN	O	O
of	NN	O	O
the	NN	O	O
T	NN	O	B-protein
cell	NN	O	I-protein
growth	NN	O	I-protein
factor	NN	O	I-protein
interleukin	NN	O	B-protein
2	NN	O	I-protein
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
the	NN	O	O
chicken	NN	O	B-protein
GATA	NN	O	I-protein
factor	NN	O	I-protein
family	NN	O	I-protein
during	NN	O	O
early	NN	O	O
erythroid	NN	O	O
development	NN	O	O
and	NN	O	O
differentiation	NN	O	O
.	NN	O	O

IL-4	NN	O	B-protein
suppressed	NN	O	O
IL-2	NN	O	O
and	NN	O	O
IFN-gamma	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
in	NN	O	O
primary	NN	O	B-cell_type
human	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
addition	NN	O	O
of	NN	O	O
anti-CD28	NN	O	B-protein
antibodies	NN	O	I-protein
relieved	NN	O	O
this	NN	O	O
suppression	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
IL-4	NN	O	B-protein
may	NN	O	O
regulate	NN	O	O
development	NN	O	O
and	NN	O	O
function	NN	O	O
of	NN	O	O
T-cell	NN	O	B-cell_type
subsets	NN	O	I-cell_type
involved	NN	O	O
in	NN	O	O
cell-mediated	NN	O	O
immunity	NN	O	O
in	NN	O	O
part	NN	O	O
by	NN	O	O
inhibiting	NN	O	B-protein
factors	NN	O	I-protein
required	NN	O	O
for	NN	O	O
transcription	NN	O	O
of	NN	O	O
the	NN	O	O
IL2	NN	O	B-DNA
gene	NN	O	I-DNA

This	NN	O	O
absence	NN	O	O
of	NN	O	O
correlation	NN	O	O
could	NN	O	O
be	NN	O	O
in	NN	O	O
part	NN	O	O
explained	NN	O	O
by	NN	O	O
the	NN	O	O
marked	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
the	NN	O	O
steroid	NN	O	O
response	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
leukocyte	NN	O	O
subpopulations	NN	O	O
.	NN	O	O

It	NN	O	O
appears	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
that	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
steroid	NN	O	O
action	NN	O	O
in	NN	O	O
vitro	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
and	NN	O	O
dexamethasone-induced	NN	O	O
cell	NN	O	O
death	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
S	NN	O	O
phase	NN	O	O
of	NN	O	O
the	NN	O	O
cell	NN	O	O
cycle	NN	O	O
.	NN	O	O

Corticosteroid-induced	NN	O	O
lymphopenia	NN	O	O
,	NN	O	O
immunosuppression	NN	O	O
,	NN	O	O
and	NN	O	O
body	NN	O	O
defense	NN	O	O
.	NN	O	O

The	NN	O	O
question	NN	O	O
is	NN	O	O
asked	NN	O	O
how	NN	O	O
this	NN	O	O
lowered	NN	O	O
defensive	NN	O	O
capability	NN	O	O
,	NN	O	O
which	NN	O	O
occurs	NN	O	O
in	NN	O	O
the	NN	O	O
face	NN	O	O
of	NN	O	O
a	NN	O	O
threat	NN	O	O
to	NN	O	O
body	NN	O	O
integrity	NN	O	O
,	NN	O	O
is	NN	O	O
consistent	NN	O	O
with	NN	O	O
Cannon	NN	O	O
's	NN	O	O
principals	NN	O	O
of	NN	O	O
the	NN	O	O
``	NN	O	O
wisdom	NN	O	O
of	NN	O	O
the	NN	O	O
body.	NN	O	O
''	NN	O	O

In	NN	O	O
vivo	NN	O	O
control	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
by	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
.	NN	O	O

The	NN	O	O
gene	NN	O	O
encoding	NN	O	O
the	NN	O	O
cytolytic	NN	O	B-protein
protein	NN	O	I-protein
perforin	NN	O	B-protein
is	NN	O	O
selectively	NN	O	O
expressed	NN	O	O
by	NN	O	O
activated	NN	O	B-cell_type
killer	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
homology	NN	O	O
between	NN	O	O
the	NN	O	O
NF-P	NN	O	B-protein
motif	NN	O	I-protein
and	NN	O	O
other	NN	O	O
Ets	NN	O	B-protein
proto-oncoprotein-binding	NN	O	I-protein
sites	NN	O	I-protein
,	NN	O	O
it	NN	O	O
is	NN	O	O
postulated	NN	O	O
that	NN	O	O
NF-P1	NN	O	B-protein
and	NN	O	O
NF-P2	NN	O	B-protein
belong	NN	O	O
to	NN	O	O
the	NN	O	O
Ets	NN	O	B-protein
protein	NN	O	I-protein
family	NN	O	I-protein
.	NN	O	O

This	NN	O	O
potent	NN	O	O
activation	NN	O	O
does	NN	O	O
not	NN	O	O
require	NN	O	O
accessory	NN	O	O
cells	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
monocytes	NN	O	B-cell_type
,	NN	O	O
but	NN	O	O
depends	NN	O	O
on	NN	O	O
persistent	NN	O	O
interleukin	NN	O	B-protein
2	NN	O	I-protein
(	NN	O	O
IL-2	NN	O	B-protein
)	NN	O	O
secretion	NN	O	O
and	NN	O	O
receptivity	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
high	NN	O	O
and	NN	O	O
prolonged	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
inducible	NN	O	O
CD25/IL-2	NN	O	B-DNA
receptor	NN	O	I-DNA
alpha	NN	O	I-DNA
(	NN	O	I-DNA
IL-2R	NN	O	I-DNA
alpha	NN	O	I-DNA
)	NN	O	I-DNA
chain	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

Vitamin	NN	O	B-protein
D	NN	O	I-protein
receptor	NN	O	I-protein
quantitation	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
blood	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
health	NN	O	O
and	NN	O	O
disease	NN	O	O
.	NN	O	O

Reactive	NN	O	O
oxygen	NN	O	O
intermediates	NN	O	O
activate	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
in	NN	O	O
a	NN	O	O
tyrosine	NN	O	O
kinase-dependent	NN	O	O
mechanism	NN	O	O
and	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
vanadate	NN	O	O
activate	NN	O	O
the	NN	O	O
p56lck	NN	O	B-protein
and	NN	O	I-protein
p59fyn	NN	O	I-protein
tyrosine	NN	O	I-protein
kinases	NN	O	I-protein
in	NN	O	O
human	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

Because	NN	O	O
H2O2	NN	O	O
is	NN	O	O
a	NN	O	O
potent	NN	O	O
ROI	NN	O	O
generator	NN	O	O
that	NN	O	O
readily	NN	O	O
crosses	NN	O	O
the	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
,	NN	O	O
we	NN	O	O
used	NN	O	O
H2O2	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
ROI	NN	O	O
on	NN	O	O
signal	NN	O	O
transduction	NN	O	O
.	NN	O	O

Despite	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	O
receptor	NN	O	O
sites	NN	O	O
per	NN	O	O
cell	NN	O	O
,	NN	O	O
the	NN	O	O
cells	NN	O	O
from	NN	O	O
the	NN	O	O
homolateral	NN	O	O
and	NN	O	O
controlateral	NN	O	O
lymph	NN	O	O
nodes	NN	O	O
were	NN	O	O
equally	NN	O	O
sensitive	NN	O	O
to	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effects	NN	O	O
of	NN	O	O
dexamethasone	NN	O	O
,	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
measurements	NN	O	O
of	NN	O	O
the	NN	O	O
incorporation	NN	O	O
of	NN	O	O
radiolabeled	NN	O	O
precursors	NN	O	O
of	NN	O	O
protein	NN	O	O
,	NN	O	O
RNA	NN	O	O
,	NN	O	O
and	NN	O	O
DNA	NN	O	O
,	NN	O	O
or	NN	O	O
measurements	NN	O	O
of	NN	O	O
in	NN	O	O
vitro	NN	O	O
cell	NN	O	O
survival	NN	O	O
.	NN	O	O

Glucocorticoid	NN	O	O
receptors	NN	O	O
and	NN	O	O
actions	NN	O	O
in	NN	O	O
rat	NN	O	B-cell_type
thymocytes	NN	O	I-cell_type
and	NN	O	O
immunologically	NN	O	O
stimulated	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
Il-4	NN	O	B-DNA
promoter/enhancer	NN	O	I-DNA
is	NN	O	O
transcriptionally	NN	O	O
inactive	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
lymphoma	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
HeLa	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
de	NN	O	O
novo	NN	O	O
gene	NN	O	O
activation	NN	O	O
in	NN	O	O
multinucleated	NN	O	B-cell_type
heterokaryons	NN	O	I-cell_type
has	NN	O	O
shown	NN	O	O
that	NN	O	O
the	NN	O	O
differentiated	NN	O	O
state	NN	O	O
,	NN	O	O
although	NN	O	O
stable	NN	O	O
,	NN	O	O
is	NN	O	O
not	NN	O	O
irreversible	NN	O	O
,	NN	O	O
and	NN	O	O
can	NN	O	O
be	NN	O	O
reprogrammed	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
appropriate	NN	O	O
combinations	NN	O	O
of	NN	O	O
trans-acting	NN	O	B-protein
regulatory	NN	O	I-protein
molecules	NN	O	I-protein
.	NN	O	O

We	NN	O	O
have	NN	O	O
tested	NN	O	O
whether	NN	O	O
breakdown	NN	O	O
of	NN	O	O
phosphatidylcholine	NN	O	O
(	NN	O	O
PC	NN	O	O
)	NN	O	O
initiated	NN	O	O
by	NN	O	O
exogenous	NN	O	O
addition	NN	O	O
of	NN	O	O
a	NN	O	O
PC-specific	NN	O	B-protein
phospholipase	NN	O	I-protein
C	NN	O	I-protein
(	NN	O	O
PC-PLC	NN	O	B-protein
)	NN	O	O
from	NN	O	O
Bacillus	NN	O	O
cereus	NN	O	O
or	NN	O	O
by	NN	O	O
endogenous	NN	O	O
overexpression	NN	O	O
of	NN	O	O
PC-PLC	NN	O	B-protein
induces	NN	O	O
functional	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
and	NN	O	O
increases	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
(	NN	O	I-DNA
HIV	NN	O	I-DNA
)	NN	O	I-DNA
enhancer	NN	O	I-DNA
activity	NN	O	O
.	NN	O	O

Dex	NN	O	O
inhibited	NN	O	O
the	NN	O	O
IL-2-dependent	NN	O	O
proliferation	NN	O	O
of	NN	O	O
PMA	NN	O	B-cell_line
blasts	NN	O	I-cell_line
in	NN	O	O
a	NN	O	O
dose-dependent	NN	O	O
fashion	NN	O	O
(	NN	O	O
IC50	NN	O	O
,	NN	O	O
5	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-8	NN	O	O
)	NN	O	O
M	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
unique	NN	O	O
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
consisted	NN	O	O
of	NN	O	O
proteins	NN	O	O
of	NN	O	O
70	NN	O	B-protein
,	NN	O	I-protein
90	NN	O	I-protein
,	NN	O	I-protein
and	NN	O	I-protein
100	NN	O	I-protein
kDa	NN	O	I-protein
with	NN	O	O
a	NN	O	O
high	NN	O	O
degree	NN	O	O
of	NN	O	O
binding	NN	O	O
specificity	NN	O	O
for	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
site	NN	O	I-protein
within	NN	O	O
the	NN	O	O
PRDII	NN	O	B-protein
domain	NN	O	I-protein
of	NN	O	O
beta	NN	O	B-protein
interferon	NN	O	I-protein
.	NN	O	O

METHODS	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
.	NN	O	O

